10 Q 2024 Q3 - Dalrada Corporation

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31,
2024

☐
TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT

For the transition period from _________ to _________

Commission File Number: 000-12641

DALRADA FINANCIAL CORPORATION

(Name of Small Business Issuer in its charter)

Wyoming	38-3713274
(state or other jurisdiction of incorporation or organization)	(I.R.S. Employer ID. No.)

600 La Terraza Blvd., Escondido, California
92025

(Address of principal executive offices)

858–283-1253

Issuer’s telephone number

Securities registered pursuant to Section 12(g)
of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.005 par value per share	DFCO	None

Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes ☒ No
☐

Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). Yes ☒ No ☐

Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of “large accelerated filer”, “accelerated filer” “smaller reporting
company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☒		Smaller reporting company ☒
		Emerging growth company ☐

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act) Yes ☐
No ☒

As of May 10, 2024, the registrant’s outstanding stock consisted
of 97,050,443 common shares.

DALRADA FINANCIAL CORPORATION.

Table of Contents

PART I – FINANCIAL INFORMATION	3

Item 1. Unaudited interim consolidated Financial Statements	3

Unaudited interim consolidated Balance Sheets	3
Unaudited interim consolidated Statements of Operations and Comprehensive Loss	4
Unaudited interim consolidated Statements of Stockholders’ Equity (Deficit)	5
Unaudited interim consolidated Statements of Cash Flows	7
Condensed Notes to the Unaudited interim consolidated Financial Statements	8

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	36
Item 3. Quantitative and Qualitative Disclosures About Market Risk	42
Item 4. Controls and Procedures	42

PART II – OTHER INFORMATION	43

Item 1. Legal Proceedings	43
Item 1A. Risk Factors	43
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Securities	43
Item 3. Defaults Upon Senior Securities	43
Item 4. Mine Safety Disclosures	43
Item 5. Other Information	43
Item 6. Exhibits	44

SIGNATURES	45

PART I – FINANCIAL INFORMATION

Item 1. Unaudited interim consolidated Financial Statements.

DALRADA FINANCIAL CORPORATION

Consolidated Balance Sheets


	March 31,			June 30,
	2024			2023
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	533,595		$	812,806
Accounts receivable, net		9,841,425			4,453,104
Accounts receivable, net – related parties		909,279			752,348
Other receivables		1,262,756			376,604
Inventories		2,753,208			2,078,692
Prepaid expenses and other current assets		582,894			1,343,491
Total current assets		15,883,157			9,817,045
Long-term receivables		20,756			41,722
Long-term receivables – related parties		1,146,064			1,173,893
Property and equipment, net		1,425,828			1,476,082
Goodwill		3,803,147			3,803,147
Intangible assets, net		3,560,524			3,858,086
Right-of-use asset, net		2,504,035			2,771,854
Right-of-use asset, net – related party		1,825,640			2,227,286
Total assets	$	30,169,151		$	25,169,115

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	5,691,861		$	5,178,897
Accrued liabilities		1,131,541			1,084,008
Accounts payable and accrued liabilities – related parties		254,295			547,949
Deferred revenue		471,423			1,337,259
Notes payable, current portion		1,733,071			439,562
Notes payable, current portion – related parties		–			251,605
Right-of-use liability		730,602			660,394
Right-of-use liability – related party		542,369			519,791
Total current liabilities		10,555,162			10,019,465
Long-term payables		–			48,888
Notes payable		2,281,129			1,011,395
Notes payable – related parties		637,688			1,648,478
Contingent consideration		4,691,794			4,285,389
Right-of-use liability		1,849,125			2,160,834
Right-of-use liability – related party		1,330,873			1,741,830
Total liabilities		21,345,771			20,916,279

Commitments and contingencies (Note 13)		–			–

Stockholders’ equity:
Preferred stock, $0.01 par value, 100,000 shares authorized:		–			–
Series I preferred stock, $0.01 par value, 51,059 and 35,108 shares issued and outstanding as of March 31, 2024 and June 30, 2023, respectively		511			351
Series H preferred stock, $0.01 par value, 15,002 shares issued and outstanding as of March 31, 2024 and June 30, 2023, respectively		150			150
Series G preferred stock, $0.01 par value, 10,002 shares issued and outstanding as of both March 31, 2024 and June 30, 2023, respectively		100			100
Series F preferred stock, $0.01 par value, 5,000 shares issued and outstanding as of both March 31, 2024 and June 30, 2023, respectively		50			50
Common stock, $0.005 par value, 500,000,000 shares authorized, 96,258,774 and 88,699,139 shares issued and outstanding at March 31, 2024 and June 30, 2023, respectively		481,294			443,478
Common stock to be issued		128,925			192,925
Additional paid-in capital		162,968,758			145,251,822
Accumulated deficit		(154,834,269	)		(141,729,009	)
Accumulated other comprehensive loss		14,707			(50,848	)
Total Dalrada Financial Corp’s stockholders’ equity		8,760,226			4,109,019
Noncontrolling interests		63,154			143,817
Total stockholders’ equity		8,823,380			4,252,836
Total liabilities and stockholders’ equity	$	30,169,151		$	25,169,115

(The accompanying notes are an integral part of
these unaudited interim consolidated financial statements)

DALRADA FINANCIAL CORPORATION

Unaudited interim consolidated Statements of Operations and Comprehensive
Loss


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2024			2023			2024			2023
Revenues	$	9,780,962		$	9,290,805			19,761,828		$	18,066,932
Revenues – related party		524,829			183,888			1,639,805			918,648
Total revenues		10,305,791			9,474,693			21,401,633			18,985,580
Cost of revenues		5,594,338			6,612,680			13,717,562			11,924,140
Gross profit		4,711,453			2,862,013			7,684,071			7,061,440

Operating expenses:
Selling, general and administrative		7,001,185			6,501,233			19,271,273			18,438,927
Total operating expenses		7,001,185			6,501,233			19,271,273			18,438,927
Loss from operations		(2,289,732	)		(3,639,220	)		(11,587,202	)		(11,377,487	)

Other income (expense):
Interest expense		(347,317	)		(314,319	)		(674,470	)		(2,207,049	)
Interest income		26,995			18,830			67,122			60,725
Other income (expense)		(196,604	)		(72,933	)		(885,303	)		(179,555	)
Gain on expiration of accrued tax liability		–			–			–			2,090,978
Gain (loss) on foreign exchange		(100,949	)		(38,156	)		(106,070	)		(85,751	)
Total other income (expense), net		(617,875	)		(406,578	)		(1,598,721	)		(320,652	)
Loss before taxes		(2,907,607	)		(4,045,798	)		(13,185,923	)		(11,698,139	)
Income taxes		–			–			–			–
Net loss		(2,907,607	)		(4,045,798	)		(13,185,923	)		(11,698,139	)

Other comprehensive loss
Foreign currency translation		19,373			(137	)		65,555			29,496
Comprehensive loss	$	(2,888,234	)	$	(4,045,935	)	$	(13,120,368	)	$	(11,668,643	)

Net income (loss) attributable to noncontrolling interests		(24,787	)		(20,234	)		(80,663	)		358,232
Net loss attributable to Dalrada Financial Corporation stockholders	$	(2,882,820	)	$	(4,025,564	)	$	(13,105,260	)	$	(12,056,371	)

Net loss per common share to Dalrada stockholders – basic	$	(0.03	)	$	(0.05	)	$	(0.14	)	$	(0.15	)
Net loss per common share to Dalrada stockholders – diluted	$	(0.03	)	$	(0.05	)	$	(0.14	)	$	(0.15	)

Weighted average common shares outstanding – basic		92,934,331			85,728,770			90,658,476			82,356,784
Weighted average common shares outstanding – diluted		92,934,331			85,728,770			90,658,476			82,356,784

(The accompanying notes are an integral part of
these unaudited interim consolidated financial statements)

DALRADA FINANCIAL CORPORATION

Unaudited Interim Consolidated Statements of Changes in Stockholders’
Equity (Deficit) for the nine months ended March 31, 2024 and 2023

Preferred Stock

Series I

Series H

Series G

Series F

Common Stock

Amount

Balance at June 30, 2022

–

10,002

100

5,000

72,174,620

360,855

Common stock issued for conversion of convertible notes, accrued interest, and premium

–

6,813,021

34,065

Common stock issues pursuant to acquisitions

–

833,333

4,167

Stock based compensation

–

500,000

2,500

Net loss

–

Foreign currency translation

–

Balance at September 30, 2022

–

10,002

100

5,000

80,320,974

401,587

Common stock issued for conversion of convertible notes, accrued interest, and premium

–

4,161,500

20,808

Common stock issues pursuant to acquisitions

–

1,175,000

5,875

Stock based compensation

–

Net loss

–

Foreign currency translation

–

Balance at December 31, 2022

–

10,002

100

5,000

85,657,474

428,270

Common stock issued for conversion of convertibles notes, accrued interest and premium

–

Common stock issued pursuant to acquisitions

–

583,333

2,917

Stock-based compensation

–

Net loss

–

Foreign currency translation

–

Balance at March 31, 2023

–

10,002

100

5,000

86,240,807

431,187

Balance at June 30, 2023

35,108

351

15,022

150

10,002

100

5,000

88,699,139

443,478

Common stock issued pursuant to acquisitions

–

234,637

1,173

Common stock issued pursuant to debt agreement

–

500,000

2,500

Conversion of related party notes into preferred stock

–

Warrants issued pursuant to acquisitions

–

Stock-based compensation

–

Net loss

–

Foreign currency translation

–

Balance at September 30, 2023

35,108

351

15,022

150

10,002

100

5,000

89,433,776

447,151

Common stock issued pursuant to acquisitions

–

458,333

2,292

Common stock issued pursuant to debt agreement

–

500,000

2,500

Warrants issued pursuant to acquisitions

–

Common stock to be issued for private placement

–

Stock-based compensation

–

Net loss

–

Foreign currency translation

–

Balance at December 31, 2023

35,108

351

15,022

150

10,002

100

5,000

90,392,109

451,943

Conversion of related party notes to preferred stock

15,951

160

–

Common stock issued pursuant to consulting agreement

–

1,200,000

6,000

Warrants issued pursuant to acquisitions

–

Common stock issued pursuant to private placement

–

4,666,665

23,351

Stock-based compensation

–

Net loss

–

Foreign currency translation

–

Balance at March 31, 2024

51,059

511

15,022

150

10,002

100

5,000

96,258,774

481,294

(The accompanying notes are an integral part of
these unaudited interim consolidated financial statements)

DALRADA FINANCIAL CORPORATION

Unaudited Interim Consolidated Statements of Changes in Stockholders’
Equity (Deficit) for the nine months ended March 31, 2024 and 2023

(Continued)


	Common Stock to be			Preferred Stock to be		Additional Paid-in		Accumulated			Accumulated Other Compre- hensive Income			Total Dalrada Financial Corp’s Stockholders’			Non- controlling			Total Stockholders’ Equity
	Issued			Issued		Capital		Deficit			(Loss)			Deficit			Interests			(Deficit)

Balance at June 30, 2022	$	1,066,925			–	$	104,627,032	$	(121,436,490	)	$	(50,673	)	$	(15,432,201	)	$	479,019		$	(14,953,182	)
Common stock issued for conversion of convertible notes, accrued interest, and premium		–			–		1,077,332		–			–			1,111,397			–			1,111,397
Common stock issues pursuant to acquisitions		(175,000	)		–		343,183		–			–			172,350			–			172,350
Stock based compensation		(175,000	)		–		640,017		–			–			467,517			–			467,517
Net loss		–			–		–		(3,617,789	)		–			(3,617,789	)		447,613			(3,170,176	)
Foreign currency translation		–			–		–		–			63,762			63,762			–			63,762
Balance at September 30, 2022		716,925			–		106,687,564		(125,054,279	)		13,089			(17,234,964	)		926,632			(16,308,332	)
Common stock issued for conversion of convertible notes, accrued interest, and premium		–			–		315,283		–			–			336,091			–			336,091
Common stock issues pursuant to acquisitions		(286,650	)		–		356,234		–			–			75,459			–			75,459
Stock based compensation		–			–		901,721		–			–			901,721			–			901,721
Net loss		–			–		–		(4,413,018	)		–			(4,413,018	)		(69,147	)		(4,482,165	)
Foreign currency translation		–			–		–		–			(34,129	)		(34,129	)		–			(34,129	)
Balance at December 31, 2022		430,275			–		108,260,802		(129,467,297	)		(21,040	)		(20,368,840	)		857,485			(19,511,355	)
Common stock issued for conversion of convertibles notes, accrued interest and premium		–			–		–		–			–			–			–			–
Common stock issued pursuant to acquisitions		(112,350	)		–		146,100		–			–			36,667			–			36,667
Stock-based compensation		–			–		815,454		–			–			815,454			–			815,454
Net loss		–			–		–		(4,025,564	)		–			(4,025,564	)		(20,234	)		(4,045,798	)
Foreign currency translation		–			–		–		–			(137	)		(137	)		–			(137	)
Balance at March 31, 2023	$	317,925		$	–	$	109,222,356	$	(133,492,861	)	$	(21,177	)	$	(23,542,420	)	$	837,251		$	(22,705,169	)


Balance at June 30, 2023		192,925			–		145,251,822		(141,729,009	)		(50,848	)		4,109,019			143,817			4,252,836
Common stock issued pursuant to acquisitions		(37,500	)		–		36,596		–			–			269			–			269
Common stock issued pursuant to debt agreement		–			–		57,500		–			–			60,000			–			60,000
Conversion of related party notes into preferred stock		–			–		–		–			–			–			–			–
Warrants issued pursuant to acquisitions		–			–		5,478		–			–			5,478			–			5,478
Stock-based compensation		–			–		1,109,642		–			–			1,109,642						1,109,642
Net loss		–			–		–		(4,816,242	)		–			(4,816,242	)		(21,894	)		(4,838,136	)
Foreign currency translation		–			–		–		–			85,208			85,208			–			85,208
Balance at September 30, 2023		155,425			–		146,461,038		(146,545,251	)		34,360			553,374			121,923			675,297
Common stock issued pursuant to acquisitions		(26,500	)		–		94,875		–			–			70,667			–			70,667
Common stock issued pursuant to debt agreement		–			–		170,500		–			–			173,000			–			173,000
Warrants issued pursuant to acquisitions		–			–		5,748		–			–			5,748			–			5,748
Common stock to be issued for private placement		604,000			–		–		–			–			604,000			–			604,000
Stock-based compensation		–			–		1,018,827		–			–			1,018,827			–			1,018,827
Net loss		–			–		–		(5,406,198	)		–			(5,406,198	)		(33,982	)		(5,440,180	)
Foreign currency translation		–			–		–		–			(39,026	)		(39,026	)		–			(39,026	)
Balance at December 31, 2023	$	732,925		$	–	$	147,750,988	$	(151,951,449	)	$	(4,666	)	$	(3,019,608	)	$	87,941		$	(2,931,667	)
Conversion of related party notes to preferred stock		–			–		13,318,783		–			–			13,318,943			–			13,318,943
Common stock issued pursuant to consulting agreement		–			–		235,200		–			–			241,200			–			241,200
Warrants issued pursuant to acquisitions		–			–		5,748		–			–			5,748			–			5,748
Common stock issued pursuant to private placement		(604,000	)		–		580,649		–			–			–			–			–
Stock-based compensation		–			–		1,077,390		–			–			1,077,390			–			1,077,390
Net loss		–			–		–		(2,882,820	)		–			(2,882,820	)		(24,787	)		(2,907,607	)
Foreign currency translation		–			–		–		–			19,373			19,373			–			19,373
Balance at March 31, 2024	$	128,925		$	–	$	162,968,758	$	(154,834,269	)	$	14,707		$	8,760,226		$	63,154		$	8,823,380

(The accompanying notes are an integral part of
these unaudited interim consolidated financial statements)

DALRADA FINANCIAL CORPORATION

Unaudited interim consolidated Statements of Cash
Flows


	Nine Months Ended March 31,
	2024			2023
Cash flows from operating activities:
Net loss	$	(13,185,923	)	$	(11,698,139	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		620,676			530,177
Stock compensation		3,205,859			2,184,692
Stock consideration issued to vendor		474,200			–
Change in fair value of contingent consideration		477,072			181,009
Provision for credit losses		527,741			640,484
Gain on expiration of accrued tax liability		–			(2,090,978	)
Changes in operating assets and liabilities, net of amounts acquired or assumed in connection with acquisition:
Accounts receivable		(6,077,304	)		(2,787,677	)
Other receivables		(859,709	)		(218,817	)
Inventories		(653,070	)		(696,695	)
Prepaid expenses and other current assets		780,979			128,542
Long-term receivables		49,013			26,889
Accounts payable		544,966			2,241,421
Long-term payables		(48,888	)		(47,329	)
Accounts payable and accrued liabilities – related parties		9,052,657			522,620
Accrued liabilities		278,429			(217,742	)
Accrued payroll taxes, penalties and interest		–			35,242
Deferred revenue		(847,240	)		1,191,593
Net cash used in operating activities		(5,660,542	)		(10,074,709	)
Cash flows from investing activities:
Purchase of property and equipment		(272,783	)		(511,515	)
Purchase of intangibles		–			(446,923	)
Acquisition of business, net of cash		–			80,087
Net cash used in investing activities		(272,783	)		(878,351	)
Cash flows from financing activities:
Proceeds from related party notes payable		2,913,980			11,845,764
Repayments of related party notes payable		(428,924	)		(752,256	)
Net proceeds (repayments) from notes payable		2,565,040			346,910
Proceeds from private placement		604,000			–
Net cash provided by financing activities		5,654,096			11,440,418
Net change in cash and cash equivalents		(279,229	)		487,358
Effect of exchange rate changes on cash		18			29,496
Cash and cash equivalents at beginning of period		812,806			772,062
Cash and cash equivalents at end of period	$	533,595		$	1,288,916

Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	–		$	–
Cash paid for interest	$	356,231		$	–

Supplemental disclosure of non-cash investing and financing activities:
Conversion of related party notes and interest into preferred stock	$	11,324,793		$	–
Conversion of accounts payable-related parties to note payable-related parties	$	1,993,990		$	–
Common stock issued pursuant to business combination	$	70,936		$	–
Conversion of convertible note payable, accrued interest and premium into common stock	$	–		$	2,327,489
Warrants issued pursuant to acquisitions	$	16,974		$	–
Operating liabilities satisfied by related parties	$	1,993,990		$	–
Increase (Decrease) in right-of-use asset and liability	$	(39,719	)	$	1,447,488

(The accompanying notes are an integral part of
these unaudited interim consolidated financial statements)

DALRADA FINANCIAL CORPORATION

Condensed Notes to the Unaudited interim consolidated Financial Statements

As of March 31, 2024

1.	Organization and Nature of Operations

Moving the world forward takes bold resolve that
turns ideas into actions and builds real-time solutions that positively impact people and the planet. Dalrada accelerates positive change
for current and future generations by harnessing true potential and developing products and services that become transformative innovations.

Dalrada Financial Corporation, (“Dalrada”
or the “Company”), was incorporated in September 1982 under the laws of the State of California. It was reincorporated in
May 1983 under the laws of the State of Delaware and reincorporated again on May 5, 2020, under the laws of the state of Wyoming. Dalrada
Financial Corporation trades under the symbol, OTCQB: DFCO.

Dalrada has five business divisions: Genefic,
Dalrada Climate Technology, Dalrada Precision Manufacturing, Dalrada Technologies and Dalrada Corporate. Within
each of these divisions, the Company drives transformative innovation while creating solutions that are sustainable, accessible, and affordable.
Dalrada’s global solutions directly address climate change, gaps in the health care industry, and technology needs that facilitate
a new era of human behavior and interaction and ensure a bright future for the world around us.

Genefic (Formerly Dalrada Health)

Genefic delivers advanced health care solutions
with dedicated products, services, and systems. From virus and disease screening capabilities to pharmaceutical goods and holistic wellness
clinics, When the world needs advanced health care, Genefic delivers with ingenuity, accessibility, and affordability. This specialized
division is committed to developing key health products, lifesaving medications and building comprehensive systems to increase capability,
strive to keep people healthy with the goals of improving their quality of life and increasing their longevity– on a global level.

Genefic Specialty Pharmacy
(“Genefic Pharmacy”)– Genefic Pharmacy (formerly Watson Rx Solutions) is an Alabama-based pharmacy with more than 30 years
of experience in the retail medical and pharmaceutical industries. Genefic Pharmacy specializes in providing expert care and managing
disease states through comprehensive prescription management, education, nursing, and total health solutions. Genefic Pharmacy maintains
pharmacy licenses in all 50 States as well as Washington D.C.

Boost Diagnostics–
Boost Diagnostics (formerly Empower Genomics and Genefic Diagnostics) is Dalrada’s wholly owned diagnostic laboratory subsidiary
which processes molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the
virus. Boost Diagnostics has built up and maintained the testing capacity to handle surges in COVID-19 testing demands. Boost Diagnostics
also offers genetic testing capabilities including Pharmacogenomics, Nutraceutical, Nutrition/Diet DNA and Exercise/Fitness DNA tests.

Pala Diagnostics (“Pala”)–
Pala was a joint venture diagnostic laboratory entity which processed both molecular diagnostic and antibody tests to support the diagnosis
of COVID-19 and the detection of immune response to the virus. Pala was no longer an operational entity as of June 30, 2023.

Dalrada Career Institute
(“DCI”) (aka International Health Group (“IHG”)) – IHG provides highly trained nursing and medical assistants
for hospitals and home health facilities since 2006. IHG Medical Assistant programs include Certified Nursing Assistant (“CNA”)
and Home Health Aide (“HHA”) training and the fast-track 22-Day CNA Certification Program at its state-approved testing facility.
DCI started its first RN, nursing class in February of 2024 and this first class will be completed in December 2024. It is the intent
of DCI to double their class size when they begin their second class in 2025.

Genefic Wellness Group
(“Genefic Wellness”)– Genefic Wellness (formerly Solas Corp.) manages and oversees wellness clinics throughout Southern
California including the Sòlas Rejuvenation + Wellness clinics (“Sòlas”). Through advanced medical techniques
and modern technology, Sòlas delivers a clinical experience that helps men and woman live their best life, whether it’s through
simple cosmetic procedures, pain-reducing practices, or anti-aging therapies. Through its three locations, Sòlas prides itself
on its dedicated service-focused, health-first approach. Its wellness & rejuvenation clinics deliver with a focus on regenerative
therapies, IV and injection services, cosmetic enhancements amongst a myriad of additional health centric services.

Dalrada Climate Technology (formerly Dalrada
Energy Services)

Dalrada Climate Technology (“DCT”)
is a segment which incapsulates energy services and state-of-the-art technology within the climate sustainability space. DCT employs next-generation
technology and services which enhances clean energy efforts while reducing the world’s carbon footprint. As a premier industrial
heat pump manufacturer, Dalrada delivers innovation and efficiency, building solutions that reduce energy consumption and minimize carbon
footprints, increase operational efficiencies, meet environmental, social, and governance (ESG) goals, and lower energy costs for clients.

Dalrada Technology
Limited (“DTL”) – DTL is a holding company for all United Kingdom and European based Dalrada Climate Technology
entities.

Likido Ltd.
(“Likido”) – Likido is an international engineering company developing advanced solutions for the harvesting and
recycling of energy. Using its novel, heat pump systems (patent pending), Likido is working to revolutionize the renewable energy
sector with the provision of innovative modular process technologies to maximize the capture and reuse of thermal energy for
integrated heating and cooling applications. With uses across industrial, commercial and residential sectors, Likido provides cost
savings and minimized carbon emissions across global supply chains. Likido’s technologies enable the effective recovery and
recycling of process energy, mitigating against climate change and expected enhancement of quality of life through the provision of
low-carbon heating and cooling systems. Likido’s products currently include the DCT One Heat Pumps (formerly
Likido®ONE) and DCT Cryo Chiller.

During the prior year, the
U.S. Government selected DCT One Series high-performance, low-carbon heat pump for real-world testing in a prestigious clean energy program.
The implementation of the DCT One Series testing is still in process. The expected positive results should not only increase market acceleration
and adoption within the federal government acceptance of groundbreaking eco-friendly technology but should also accelerate adoption within
the commercial building industry.

Dalrada Technology Spain
L.T. (“DTS”)- DTS was established as a Spanish subsidiary of DTL for the expansion of the manufacturing and sale of the
DCT One Series and DCT Cryo Chiller throughout Europe.

Dalrada Energy Services
(“DES”)– DES provides end-to-end comprehensive energy service solutions in a robust commercial capacity. DES helps organizations
meet ESG goals and standards while mitigating negative environmental impacts.

Bothof Brothers Construction
(“Bothof”)– Bothof is a licensed general contractor which provides a wide range of development, construction and design
capabilities and expertise throughout the United States. Through Bothof’s extensive experience in construction and contracting,
the DES division can provide a myriad of additional services to its private and public works customers.

Dalrada Financial Corporation
Morocco (“DFCM”)- DFCM was established as a Moroccan subsidiary of Dalrada to conduct energy service solutions within
the country of Morocco. Dalrada owns a 33% equity interest in DFCM.

Dalrada Home Corporation
(“Dalrada Home”)- Dalrada Home Corporation was established in February of 2024. Dalrada Home’s cutting-edge sustainability
solutions are designed specifically for residential purposes. Our home heat pumps help us lead the way in providing innovative climate
technology products and services to residential customers.

Dalrada Precision Manufacturing

Dalrada Precision Manufacturing creates total
manufacturing solutions that start with the design and development of high-quality machine parts and components, and end with an efficient
global supply chain. This specialized business division can meet today’s high demands and solves industry challenges. Dalrada Precision
Manufacturing is confident that it redefines the critical quality of the world’s top components and responds with in-house research,
design, engineering, and distribution through a highly reliable global supply chain and improved time-to-market capabilities.

Dalrada Precision
Parts (“Precision”) – Precision extends the client its engineering and operations team by helping devise unique
manufacturing solutions tailored to their products. Dalrada Precision can enter at any stage of the product lifecycle from concept
and design to mass production and logistics.

Deposition
Technologies (“DepTec”) – DepTec designs, develops, manufactures, and services chemical vapor and physical vapor
deposition systems for the microchip and semiconductor industries.

DepTec has built an impressive
catalogue of precision OEM parts for PVD (Physical vapor deposition) systems and the Company’s refurbished systems which allows
clients the option of purchasing the same model of system they’ve been using for decades –but with significant upgrades and
improved efficiencies. Older systems can now operate more reliably with additional control and monitoring plus longer lifespans. DepTec
also has its own PVD and CVD (Chemical Vapor Deposition) systems, EVOS-PVD and EVOS -CVD, which deposits metals and non-metals for microchips
used in almost every standard and specialized microdevices made today and in the future. These systems can produce a superior film layer
utilized in rugged high-stress environment designs.

Ignite I.T.
(“Ignite”) – Ignite is a manufacturer and seller of eco-friendly deep cleaners, parts washers and degreasers that
are specially formulated to lift hydrocarbon-based dirt and grease from virtually all surfaces with minimal effort. Ignite products
are non-flammable, non-corrosive, non-toxic, butyl-free, water-based, and leave a light citrus scent. Ignite is developed for all
surfaces suitable for water and meets or exceed the most stringent industry-testing specifications.

Dalrada Technologies

Dalrada Technologies has worked with some of the
world’s most recognizable companies, providing digital engineering for cutting-edge software systems and offering a host of robust
digital services. This business division connects the world with integrated technology and innovative solutions, delivering advanced capabilities
and error-free results. Dalrada Technologies creates digital products with expert computer information technology and software engineering
services for a variety of technical industries and clients in both B2B and B2C environments.

Prakat
(“Prakat”) – Prakat is an ISO 9001-certified company that provides end-to-end technology services across various
industries, improving the value chain. The Company specializes in test engineering, accessibility engineering, product engineering,
application modernization, billing and revenue management, CRM, and block chain. Prakat provides global customers with software and
technology solutions specializing in Test Engineering, Accessibility Engineering, Product Engineering and Application
Modernization.

Dalrada Corporate

Dalrada Corporate covers the activities which
support the entire suite of Dalrada subsidiaries. Dalrada Corporate includes the areas of administration, finance, human resources, legal
advice, information technology, and marketing. It also contains executive management and shareholder-related services.

Going Concern

These unaudited interim consolidated
financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets
and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon
the continued financial support from related parties, its ability to identify future investment opportunities, obtain the necessary
debt or equity financing, and generate profitable operations. The Company had net losses of approximately $13.1
million, accumulated deficit of $154.8
million and net cash used in operations of $5.7
million for the nine months ended March 31, 2024. These factors raise substantial doubt regarding the Company’s ability to
continue as a going concern for a period of twelve months from the issue date of this report. These consolidated financial
statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of
liabilities that might be necessary should the Company be unable to continue as a going concern.

2.	Summary of Significant Accounting Policies

(a)

Basis of Presentation

These unaudited interim consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (“US GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities
and Exchange Commission (“SEC”). Accordingly, certain information and disclosures required by US GAAP for annual financial
statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary
for a fair presentation have been included. Unless otherwise indicated, balances are expressed in U.S. dollars. These unaudited interim
consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes
thereto as of and for the year ended June 30, 2023 (the “2023 Annual Audited Financials”), included in the Company’s
Annual Report on Form 10-K filed with the SEC on October 19, 2023 (the “Form 10-K”). The results of operations as of and for
the three and nine months ended March 31, 2024 are not necessarily indicative of the results to be expected for the 2024 full year or
any future periods. The accompanying consolidated balance sheet as of June 30, 2023 has been derived from the audited consolidated balance
sheet as of June 30, 2023 contained in the 2023 Annual Audited Financials included in the Form 10-K.

(b)

Principles of Consolidation

The unaudited interim consolidated
financial statements include the accounts of the Company and its subsidiaries, as well as the accounts of any entities over which the
Company has a controlling financial interest in accordance with Accounting Standards Codification (“ASC”) 810 Consolidation.
All transactions and balances between these entities have been eliminated upon consolidation.

Income attributable to the minority
interest in the Company’s majority owned and controlled consolidated subsidiaries is recorded as net income attributable to noncontrolling
interests in the Consolidated Statements of Operations and Comprehensive Loss and the noncontrolling interest is reflected as a separate
component of the Consolidated Statements of Stockholders’ Equity, Consolidated Balance Sheets, and Consolidated Statements of Cash
Flows.

(c)

Use of Estimates

The preparation of these unaudited
interim consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions related to the revenue, valuation of inventory, valuation of acquired assets and liabilities, variables used in the computation
of share-based compensation, litigation, contingent consideration, and evaluation of goodwill and intangible assets for impairment.

The Company bases its estimates and
assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs
and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and
adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results,
future results of operations will be affected.

(d)

Concentrations of Credit Risk

Financial instruments that potentially
subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, as well as accounts receivable.
The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high
credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and
cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial
banking relationships.

When estimating its allowance for credit
losses related to revenues from Covid Testing and pharmacy sales, the Company differentiates its receivables based on the following customer
types: healthcare insurers, government payers, and cash payers. Additionally, the Company applies assumptions and judgments for assessing
collectability and determining net revenues and accounts receivable from its customers. Management considers various historical collection
factors for assessing collectability and determining net revenues and accounts receivable from our customers which include the period
that the receivables have been outstanding, history of payment amounts, status of collections due, and applicable statutes of limitations.

During the nine months ended March
31, 2024 and 2023, healthcare insurers, government payers and OTC pharmaceutical sales accounted for over 64%, and 28% of total revenues,
respectively. Also, healthcare insurers, government payers and OTC pharmaceutical sales amounted to total revenues of $14,012,544 and
$5,567,245 for the nine months ended March 31, 2024 and 2023, respectively. The accounts receivable related to both healthcare insurers
and government payers is $8,670,069 and $1,499,415 as of March 31, 2024 and June 30, 2023, respectively.

As of March 31, 2024 and June 30,
2023, $612,803
and $829,239
is owed by customers from the sale of DCT One units, respectively.

(e)

Fair Value Measurements

Pursuant to ASC 820, Fair Value
Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding
the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the
lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be
used to measure fair value:

Level 1 – applies to assets or liabilities
for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 – applies to assets or liabilities
for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets
or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent
transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally
from, or corroborated by, observable market data.

Level 3 – applies to assets or liabilities
for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the
assets or liabilities.

The Company’s financial instruments
consist principally of cash, accounts receivable, accounts payable and accrued liabilities, notes payable, and amounts due to related
parties. Pursuant to ASC 820, the fair value of cash is determined based on “Level 1” inputs, which consist of quoted prices
in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because
of their nature and respective maturity dates or durations.

The fair value of the contingent consideration
obligations was based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment
with respect to the likelihood of achieving those criteria. The measurement was based on significant inputs that were not observable
in the market, therefore, the Company classified this liability as Level 3 in the following tables:

Schedule of fair value of liabilities
	Fair Value Measurements as of March 31, 2024 Using:
	Level 1		Level 2		Level 3		Total
Liabilities:
Contingent consideration		–		–	$	4,691,794	$	4,691,794
	$	–	$	–	$	4,691,794	$	4,691,794

	Fair Value Measurements as of June 30, 2023 Using:
	Level 1		Level 2		Level 3		Total
Liabilities:
Contingent consideration		–		–	$	4,285,389	$	4,285,389
	$	–	$	–	$	4,285,389	$	4,285,389

The Company records a contingent consideration
liability relating to stock price guarantees included in its acquisition and consulting agreements. The estimated fair value of the contingent
consideration is recorded using a significant observable measure and is therefore classified as a Level 3 financial instrument.

The fair value of the contingent consideration
liability related to the Company’s business combinations is valued based on a forward contract and the guaranteed equity value at
settlement as defined in the acquisition agreement (see “Note 4. Business Combinations and Asset Acquisition). The fair value of
the contingent consideration is then calculated based on the guaranteed equity value at settlement as defined in the acquisition agreement.
(See “Note 13. Commitments and Contingencies”).

Changes in contingent consideration
liability during the nine months ended March 31, 2024 and the year ended June 30, 2023, are as follows:


	Contingent Consideration Liability
Balance as of June 30, 2022	$	4,870,800
Change in fair value		(585,411	)
Balance as of June 30, 2023	$	4,285,389

	Contingent Consideration Liability
Balance as of June 30, 2023	$	4,285,389
Change in fair value		477,072
Common stock issuance		(70,667	)
Balance as of March 31, 2024	$	4,691,794

(f)

Convertible Instruments

The Company evaluates and accounts
for conversion options embedded in convertible instruments in accordance with ASC Topic 815, Derivatives and Hedging Activities (“ASC
815”).

Applicable U.S. GAAP requires companies
to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according
to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument
that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable
generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument
with the same terms as the embedded derivative instrument would be considered a derivative instrument.

The Company accounts for convertible
instruments (when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments)
as follows. The Company records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in shares based
upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective
conversion price embedded in the shares. There was no derivative liability as of March 31, 2024.

(g)

Accounts Receivable

Accounts receivables are derived
from products and services delivered to customers and are stated at their net realizable value. Each month, the Company reviews its
receivables on a customer-by-customer basis and evaluates whether an allowance for expected credit losses is necessary based on any
known or perceived collection issues. Any balances that are eventually deemed uncollectible are written off against the allowance
after all means of collection have been exhausted and the potential for recovery is considered remote. As of March 31, 2024, and
June 30, 2023, the Company had an allowance for expected credit losses of $557,401
and $2,430,615
respectively.

Genefic Pharmacy, Boost, and Pala have
a standardized approach to estimate the amount of consideration that we expect to be entitled to for its pharmaceutical revenue, and COVID-19
testing including the impact of contractual allowances (including payer denials), and patient price concessions. The Company principally
estimates the allowance for credit losses by pool based on historical collection experience, the current credit worthiness of the customers,
current economic conditions, expectations of future economic conditions and the period of time that the receivables have been outstanding.
Adjustments to our estimated contractual allowances and implicit patient price concessions are recorded in the current period as changes
in estimates.

(h)

Inventory

Inventory is recorded at the lower
of cost or net realizable value on a first-in first-out basis. As of the nine months ended March 31, 2024, and year ended June 30, 2023,
inventory is comprised of raw materials purchased from suppliers, work-in-progress, and finished goods produced or purchased for resale.
The Company establishes inventory reserves for estimated obsolete or unsaleable inventory equal to the difference between the cost of
inventory and the estimated realizable value based upon assumptions about future market conditions. No reserve was established as of March 31, 2024 and June 30, 2023.

(i)

Property and Equipment

Property and equipment are stated
at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method
over the estimated useful life of each asset, as follows:


		Estimated Useful Life
Computer and office equipment		3 – 5 years
Machinery and equipment		5 years
Leasehold improvements		Shorter of lease term or useful life

Estimated useful lives are periodically
assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired
or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the Consolidated
Balance Sheet and any resulting gains or losses are included in the Consolidated Statement of Operations in the period of disposal.

(j)

Business Combinations and Acquisitions

The Company accounts for acquisitions
in which it obtains control of one or more businesses as a business combination. The purchase price of the acquired businesses is allocated
to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. The
excess of the purchase price over those fair values is recognized as goodwill. During the measurement period, which may be up to one year
from the acquisition date, the Company may record adjustments, in the period in which they are determined, to the assets acquired and
liabilities assumed with the corresponding offset to goodwill. If the assets acquired are not a business, the Company accounts for the
transaction or other event as an asset acquisition. Under both methods, the Company recognizes the identifiable assets acquired, the liabilities
assumed, and any noncontrolling interest in the acquired entity. In addition, for transactions that are business combinations, the Company
evaluates the existence of goodwill, indefinite life intangible assets, or a gain from a bargain purchase.

(k)

Contingent Consideration

Certain acquisitions include contingent
consideration as part of the purchase price. The fair value of the contingent consideration is estimated as of the acquisition date based
on the present value of the contingent payments to be made using a weighted probability of possible payments. The unobservable inputs
used in the determination of the fair value of the contingent consideration include managements assumptions about the likelihood of payment
based on the established benchmarks and discount rates based on internal rate of return analysis. The fair value measurement includes
inputs that are Level 3 measurement as discussed in Note 4 to our consolidated financial statements included in this quarterly report
on Form 10-Q. Should actual results increase or decrease as compared to the assumption used in our analysis, the fair value of the contingent
consideration obligations will increase or decrease, up to the contracted limit, as applicable. Changes in the fair value of the contingent
earn-out consideration could cause a material impact and volatility in our operating results. The fair value of the contingent consideration
increased by $289,400 and $477,072 to a balance of $4,691,794 during the three and nine months ended March 31, 2024, respectively.

In December 2023, the Company issued
333,333 shares of common stock related to the acquisition of DepTec (SSCe) for $70,667.

(l)

Impairment of Long-Lived Assets

The Company reviews its long-lived
assets (property and equipment and amortizable intangible assets) for impairment whenever events or circumstances indicate that the carrying
amount of an asset may not be recoverable. If the sum of the expected cash flows, undiscounted, is less than the carrying amount of the
asset, an impairment loss is recognized as the amount by which the carrying amount of the asset exceeds its fair value.

Goodwill is tested annually at June
30 for impairment and upon the occurrence of certain events or substantive changes in circumstances.

The annual goodwill impairment test
allows for the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting
unit is less than its carrying amount. An entity may choose to perform the qualitative assessment on none, some or all of its reporting
units or an entity may bypass the qualitative assessment for any reporting unit and proceed directly to step one of the quantitative impairment
tests. If it is determined, on the basis of qualitative factors, that the fair value of a reporting unit is, more likely than not, less
than its carrying value, the quantitative impairment test is required. The quantitative impairment test calculates any goodwill impairment
as the difference between the carrying amount of a reporting unit and its fair value, but not to exceed the carrying amount of goodwill.
As of June 30, 2023, there were quantitative factors that indicated goodwill was impaired in the amount of $433,556. During the nine months
ended March 31, 2024, the Company performed a qualitative assessment of its reporting units to evaluate whether it is more likely than
not that the fair value of a reporting unit is less than its carrying amount. As a result of the qualitative impairment assessment performed,
the Company did not recognize goodwill impairment.

An intangible asset is an identifiable
non-monetary asset without physical substance. Such an asset is identifiable when it is separable, or when it arises from contractual
or other legal rights. Separable assets can be sold, transferred, licensed, etc. Examples of intangible assets include computer software,
licenses, trademarks, patents, films, and copyrights. The Company’s intangible assets are finite lived assets and are amortized
on a straight-line basis over the estimated useful lives of the assets.

(m)

Revenue Recognition

The Company determines revenue recognition
in accordance with Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers, and its
related amendments (collectively known as “ASC 606”) through the following steps:

	–	Identification of a contract with a customer;

	–	Identification of the performance obligations in the contract;

	–	Determination of the transaction price;

	–	Allocation of the transaction price to the performance obligations in the contract; and

	–	Recognition of revenue when or as the performance obligations are satisfied.

Revenue is recognized when control
of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be
entitled to in exchange for those goods or services. As a practical expedient, the Company does not adjust the transaction price for the
effects of a significant financing component if, at contract inception, the period between customer payment and the transfer of goods
or services is expected to be one year or less.

The Company’s revenue is primarily
derived from the sales of its products, which represents net sales recorded in the Company’s Consolidated Statements of Operations.
Product sales are recognized at a point in time when performance obligations under the terms of the contract with the customer are satisfied.
Typically, this would occur upon transfer of control, including passage of title to the customer and transfer of risk of loss related
to those goods. The Company measures revenue as the amount of consideration to which it expects to be entitled in exchange for transferring
goods (transaction price). The Company records reductions to revenue for estimated customer returns, allowances, markdowns, and discounts.
The Company bases its estimates on historical rates of customer returns and allowances as well as the specific identification of outstanding
returns, markdowns and allowances that have not yet been received by the Company. The actual amount of customer returns and allowances
is inherently uncertain and may differ from the Company’s estimates. If the Company determines that actual or expected returns or
allowances are significantly higher or lower than the reserves it established, it will record a reduction or increase, as appropriate,
to net sales in the period in which it makes such a determination. Reserves for returns and markdowns are included within accrued expenses
and other liabilities in the Company’s Consolidated Balance Sheets. Allowance and discounts are recorded in accounts receivable,
net and the value of inventory associated with reserves for sales returns are included within prepaid expenses and other current assets
in the Consolidated Balance Sheets.

The Company estimates warranty
claims reserves based on historical results and research and determined that a warranty reserve was not
necessary as of March 31, 2024 or June 30, 2023.

Net revenues from Pharmaceutical sales
and COVID-19 testing accounted for over 64% and 28% of the Company’s total net revenues for the nine months ended March 31, 2024
and nine months ended March 31, 2023, respectively, and primarily comprised of a high volume of relatively low-dollar transactions. Pala
and Boost, which provides clinical testing services and other services, satisfies its performance obligations and recognizes revenues
primarily upon completion of the testing process (when results are reported) or when services have been rendered at a point in time. Genefic
Pharmacy directly bills patients as well as insurers and government agencies. Pala and Boost do not invoice the patients themselves for
testing but relies on healthcare insurers and government payers for reimbursement for COVID-19 testing. Pala has a standardized approach
to estimate the amount of consideration that we expect to be entitled to, including the impact of contractual allowances (including payer
denials), and patient price concessions. We regularly assess the state of our billing operations in order to identify issues which may
impact the collectability of receivables or revenue estimates. We believe that the collectability of our receivables is directly linked
to the quality of our billing processes, most notably those related to obtaining the correct information in order to bill effectively
for the services we provide. As such, we strive to implement “best practices” and work with our third-party billing company
to reduce the number of requisitions that we receive from healthcare providers with missing or incorrect billing information. We believe
that our collection and revenue estimation processes, along with our close monitoring of our billing operations, help to reduce the risk
associated with material adjustments to reserve estimates. However, changes to our estimate of the impact of contractual allowances (including
payer denials) and patient price concessions could have a material impact on our results of operations and financial condition in the
period that the estimates are adjusted. Adjustments to our estimated contractual allowances and implicit patient price concessions are
recorded in the current period as changes in estimates. Although we have limited track record, further adjustments to the allowances,
based on actual receipts, may be recorded upon settlement.

DES recognizes service revenue on energy
savings contracts where it provides design, engineering and equipment upgrades to obtain energy savings through Environmental, Social,
and Governance (“ESG”) targets. DES recognizes revenue through two performance obligations: 1) the Energy Savings Report (point
in time); and 2) functional IP license (point in time with a significant financing component and royalty and variable consideration constraint).
Up to and upon completion of an energy savings project, DES calculates the monthly energy savings based on prior and current energy consumption
totals. Upon completion of a project, the customer pays monthly fixed payments which represents a financing component. DES recognized
monthly interest income and “royalty” revenue when the constraint from the energy savings percentage is known. DES records
revenue at a point in time as it provides additional management, consulting, and other services as they are incurred.

DepTec and Bothof recognize service
revenues at a point in time using a cost-based input method, by which we use actual costs incurred relative to the total estimated contract
costs to determine, as a percentage, progress toward contract completion. Provisions for estimated losses on uncompleted contracts are
made in the period in which such losses are determined. The unbilled portion in excess of costs incurred is reflected as an other receivable
in the Company’s Consolidated Balance Sheets.

The Company also earns service revenue
from its other subsidiaries, including information technology and consulting services via Prakat, educational programs, and courses via
DCI, management services for Genefic Wellness Group, and custom parts manufacturing for Dalrada Precision Parts. For Prakat, Genefic Wellness
Group and Dalrada Precision Parts, revenues are recognized when performance obligations have been satisfied and the services are complete.
This is generally at a point of time upon written completion and client acceptance of the project or product, which represents transfer
of control to the customer. For DCI, service revenues are recognized over the course of a semester while services are performed.

Disaggregation of Revenue

The following table presents the Company’s
revenue disaggregated by revenue source:

Schedule of disaggregated revenue
	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2024		2023		2024		2023
Product sales – third parties	$	8,629,380	$	2,878,093	$	16,426,566	$	5,390,857
Product sales – related party		–		1,336		140		75,335
Service revenue – third parties		1,151,582		6,412,712		3,335,262		12,676,075
Service revenue – related party		524,829		182,552		1,639,665		843,313
Total revenue	$	10,305,791	$	9,474,693	$	21,401,633	$	18,985,580

Accounts Receivable and Deferred
Revenue

The following table provides information
about receivables and contract liabilities from contracts with customers:


	March 31,		June 30,
	2024		2023
Accounts receivable, net	$	9,841,425	$	4,453,104
Accounts receivable, net – related parties		909,279		752,348
Long-term receivables		20,756		41,722
Long-term receivables – related parties		1,146,064		1,173,893
Deferred revenue		471,423		1,337,259

The Company invoices customers based
upon contractual billing schedules, and accounts receivable are recorded when the right to consideration becomes unconditional. Contract
liabilities represent a set-up fee prepayment received from a customer in advance of performance obligations met.

(n)

Cost of Revenue

Cost of revenue consists primarily
of inventory sold for product sales and direct labor for information technology and consulting services. The following table is a breakdown
of cost of revenue:

Schedule of cost of revenue
	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2024		2023		2024		2023
Product sales	$	4,014,290	$	1,617,124	$	8,749,074	$	3,320,438
Service revenue		1,580,048		4,995,556		4,968,488		8,603,702
Total cost of revenue	$	5,594,338	$	6,612,680	$	13,717,562	$	11,924,140

(o)

Advertising

Advertising costs are expensed as incurred.
During the three months ended March 31, 2024 and 2023, advertising expenses were approximately $55,265 and $75,235, respectively. During
the nine months ended March 31, 2024 and 2023, advertising expenses were approximately $144,185 and $275,846, respectively.

(p)

Stock-based Compensation

The Company records stock-based compensation
in accordance with ASC 718, Compensation – Stock Compensation using the fair value method. All transactions in which goods
or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration
received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees
and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued.
During the three months ended March 31, 2024 and 2023, stock-based compensation was $1,077,390 and $815,454, respectively. During the
nine months ended March 31, 2024 and 2023, stock-based compensation expense was $3,205,859 and $2,184,692, respectively

(q)

Foreign Currency Translation

The functional currency of the Company
is the United States dollar. The functional currency of the Likido, DepTec, and Dalrada Technology subsidiaries is the Great British Pound.
The functional currency of Prakat is the Indian Rupee. The functional currency of Dalrada Technology Spain is the Euro. The financial
statements of the Company’s subsidiaries were translated to United States dollars in accordance with ASC 830, Foreign Currency
Translation Matters, using period-end rates of exchange for assets and liabilities, and average rates of exchange for the year for
revenues and expenses. Gains and losses arising on foreign currency denominated transactions are included in Consolidated Statements of
Operations.

(r)

Comprehensive Loss

ASC 220, Comprehensive Income, establishes
standards for the reporting and display of comprehensive loss and its components in the consolidated financial statements. During the
three and nine months ended March 31, 2024, and 2023, the Company’s only component of comprehensive loss was foreign currency translation
adjustments.

(s)

Non-controlling Interests

Non-controlling interests are classified
as a separate component of equity in the Company’s Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders’
Equity (Deficit). Net loss attributable to non-controlling interests are reflected separately from consolidated net loss in the Consolidated
Statements of Comprehensive Loss and Consolidated Statements of Changes in Stockholders’ Equity (Deficit). Any change in ownership
of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling
and non-controlling interests. In addition, when a subsidiary is deconsolidated, any retained non-controlling equity investment in the
former subsidiary will be initially measured at fair value and the difference between the carrying value and fair value of the retained
interest will be recorded as a gain or loss.

As of March 31, 2024, and June 30,
2023, non-controlling interests pertained to the Company’s Dalrada Morocco, Prakat and Pala subsidiaries in the amount of 67.0%,
25.4%, and 48.0%, respectively.

(t)

Basic and Diluted Net Loss per Share

The Company computes net income (loss)
per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per
share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common
shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect
to all dilutive potential common shares outstanding during the periods using the treasury stock method and convertible preferred stock
using the if-converted method. In computing diluted EPS, the average stock price for the periods is used in determining the number of
shares assumed to be purchased from the exercise of warrants.

The weighted average number of common
stock equivalents related to cashless warrants of 67,017,134 and 0, was not included in diluted loss per share, because the effects are
antidilutive, for the nine months ended March 31, 2024 and 2023, respectively.

There were no adjustments to the numerator
during the three and nine months ended March 31, 2024 and 2023.

(u)

Income Taxes

The Company accounts for income taxes
using the asset and liability method in accordance with ASC 740, Accounting for Income Taxes. The asset and liability method provides
that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the
financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carryforwards. Deferred tax assets
and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to
reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to
be realized. The Company had a full valuation allowance at March 31, 2024 and June 30, 2023

(v)

Recent Accounting Pronouncements

The Company has implemented all new
accounting pronouncements that are in effect and that may impact its unaudited interim consolidated financial statements and does not
believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial
position or results of operations.

(w)

Reclassification

During the three months ended March
31, 2024, the company reclassified $3,851 of additional paid in capital to common stock par value and $604,000 from additional paid in
capital and common stock par value to common stock to be issued. The reclassification had no impact on total operating costs, loss
from operations, net loss, earnings per share or total equity.

3.	Investment in Pala Diagnostics

In August 2021, Dalrada, through its subsidiary
Dalrada Health, entered a joint venture (“JV”) with Vivera Pharmaceuticals, Inc (“Vivera”) for a 51%
ownership and controlling interest. The JV, Pala Diagnostics, LLC (“Pala”) is a CLIA-certified diagnostics lab focused on
SARS-CoV-2 testing for now with additional testing capabilities to be introduced. The JV has been treated as a business combination.

Pursuant to the partnership agreement, Dalrada
contributed equity in the amount of $500,000 for operating capital and Vivera contributed property and equipment at a fair value of $111,185.
This amount was included in non-controlling interest equity balance in the Consolidated Balance Sheets.

Pursuant to the JV agreement, Dalrada issued 250,000
shares of common stock to Vivera in October 2021. The fair value of $58,560 was recorded as a loss on impairment in full for the fiscal
year ending June 30, 2023.

In December 2021, Dalrada Health filed suit against
Vivera and Paul Edalat, Vivera’s Chairman and CEO, for misappropriation of funds on behalf of the joint venture in the amount of
$2,104,509, accounted for as an unauthorized distribution. In addition to filing a cross-complaint against Dalrada Health Products, Vivera
filed a separate complaint against Dalrada Financial Corporation, Empower Genomics, Dalrada Financial Corporation’s officers, and
other unrelated parties. See Note 13 – Commitments and Contingencies for legal proceedings.

4.	Business Combinations and Asset Acquisition

Bothof Brothers Construction Inc. (“Bothof”)

On October 17, 2022, the Company acquired 100%
of the common stock of Bothof. The Company assumed the net liabilities of the Bothof in exchange for the employment services of the selling
shareholder. All considerations in the transaction required the continued employment of the selling shareholder and thus is not consideration
transferred under ASC 805.

The Company entered into a 36-month employment
agreement with the selling shareholder for $30,000 monthly and additionally issued 3,000,000 cashless warrants, at a strike price of $0.15
per share, to equal $450,000, which vest quarterly over a period of 24 months (the “Warrant Consideration”).

If at the end of the 24-month warrant distribution
period, beginning on the effective date of October 17, 2022 (the “Distribution Period”), the value of cashless warrants does
not equate to $6,000,000 (the “Target Amount”) in value, then the Company shall issue additional cashless warrants equal to
the shortfall between the value of the Warrants Consideration and the Target Amount (the “Valuation Shortfall”).

The value of the Warrant Consideration to the
selling shareholder is $3,482,550. The Company records the value as stock-based compensation on a straight-line basis over the vesting
period of 24-months.

The Warrant Consideration is contingent on the
selling shareholder’s continued employment with the Company; therefore, it is treated as stock-based compensation expense and recognized
ratably over a 24-month period.

The Company acquired Bothof to facilitate the
work of and expand the Dalrada Energy Services segment. Bothof’s selling shareholder holds certain licenses, construction/engineering
design expertise and management skills which will leverage synergies with Dalrada Energy Services.

The Bothof transaction was accounted for as a
business combination in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities
assumed.

The Company has made a preliminary allocation
of the purchase price regarding the acquisition related to the assets acquired and liabilities assumed as of the purchase date. The following
table summarizes the purchase price allocation as of October 17, 2022:

Schedule of purchase price allocation
	Preliminary Purchase Price Allocation
Cash and cash equivalents	$	70,979
Other receivables		27,289
Right of use asset, net		18,618
Property and equipment, net		17,179
Trade name		6,776
Accounts payable		(24,165	)
Accrued liabilities		(18,807	)
Deferred revenue		(60,000	)
Right of use liability		(18,618	)
Notes payable, current portion		(19,251	)
Purchase price consideration	$	–

Trade name is amortized on a straight-line basis
over one month. The fair value estimate of the trade name for the purchase price allocation was based on an analysis of the present value
of future cash flows and relief from royalty method.

Dalrada Technology LTD EU (“DTL”)

On March 1, 2023, the Company acquired 100% of
the common stock of DTL in an asset acquisition. In consideration for the asset acquisition, the Company issued 1,000,000 cashless warrants,
at a strike price of $0.10 per share, which shall vest quarterly over 36 months.

The value of the Warrant Consideration to the
selling shareholder is $68,975. The value was calculated using the Black-Scholes model. The Company recorded a liability for the warrants
at the acquisition date as the warrants are not contingent on employment of the sellers.

The Company acquired DTL as a holding company
for its European operations, including Likido Ltd. and DepTec. DTL will also be utilized to pursue certain European grants and other governmental
funding opportunities. The two sellers of DTL are related parties to the Chairman and CEO of the Company.

The DTL transaction was accounted for as an asset
acquisition in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities assumed.

The Company has made a preliminary allocation
of the purchase price regarding the asset acquisition related to the assets acquired and liabilities assumed as of the purchase date.
The following table summarizes the purchase price allocation as of March 1, 2023:

Schedule of purchase price allocation
	Preliminary Purchase Price Allocation
Cash and cash equivalents	$	9,108
Deposits		13,536
Prepaids		24,666
Furniture and Fixtures		64,533
Trade name		206,336
Loan Payable		(249,204	)
Purchase price consideration	$	68,975

Trade name is amortized on a straight-line basis over two years.

5.	Selected Balance Sheet Elements

Inventories

Inventories consisted of the following as of March 31, 2024 and June
30, 2023:

Schedule of inventories
	March 31,		June 30,
	2024		2023
Raw materials	$	955,568	$	658,175
Work-in-progress		1,218,522		708,007
Finished goods		579,118		712,510
Inventories	$	2,753,208	$	2,078,692

Property and Equipment, Net

Property and equipment, net consisted of the following as of March
31, 2024 and June 30, 2023:

Schedule of property and equipment, net
	March 31,			June 30,
	2024			2023
Machinery and equipment	$	1,603,545		$	1,448,556
Leasehold improvements		409,480			208,689
Computer and office equipment		470,003			426,162
Construction in progress		–			249,613
Property and equipment, gross		2,483,028			2,333,020
Less: Accumulated depreciation		(1,057,200	)		(856,938	)
Property and equipment, net	$	1,425,828		$	1,476,082

Depreciation expense of $323,114 and $265,749
for the nine months ended, and $170,688 and $94,331 for the three months ended, March 31, 2024, and 2023, respectively, were included
in selling, general and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss.

Intangible Assets, Net

Intangible assets, net consisted of the following
as of March 31, 2024:

Schedule of intangible assets, net
													Developed
													technology,
	Curriculum						Customer						software,
	development			Licenses			relationships			Trademarks			and other			Totals
Balance: June 30, 2023	$	693,385		$	1,064,000		$	1,244,480		$	535,547		$	813,479		$	4,350,891
Additions		–			–			–			–			–			–
Balance: March 31, 2024		693,385			1,064,000			1,244,480			535,547			813,479			4,350,891

Less: Accumulated amortization
Balance: June 30, 2023		(172,230	)		(55,378	)		(153,770	)		(54,595	)		(56,832	)		(492,805	)
Additions		(52,005	)		(42,893	)		(78,843	)		(75,451	)		(48,370	)		(297,562	)
Balance: March 31, 2024		(224,235	)		(98,271	)		(232,613	)		(130,046	)		(105,202	)		(790,367	)

Net book value: March 31, 2024	$	469,150		$	965,729		$	1,011,867		$	405,501		$	708,277		$	3,560,524

Amortization expense of $297,562 and $264,428
for the nine months ended, and $94,299 and $87,334 for the three months ended, March 31, 2024, and 2023, respectively, were included in
selling, general and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss. The Company’s
intangible assets are subject to amortization and are amortized over the straight-line methods over their estimated period of benefit.

6.	Notes Payable

Notes Payable – Related Parties

The following is a summary of notes payable –
related parties on March 31, 2024 and June 30, 2023:


	March 31, 2024
	Outstanding		Accrued
	Principal		Interest
Related entity 1	$	–	$	–
Related entity 2		304,684		–
Related entity 3		–		–
Related entity 4		333,004		–
Related entity 5		–		–
Related entity 6		–		–
	$	637,688	$	–

	June 30, 2023
	Outstanding		Accrued
	Principal		Interest
Related entity 1	$	1,380,672	$	3,038
Related entity 2		126,864		–
Related entity 3		105,000		–
Related entity 4		50,074		–
Related entity 5		–		–
Related entity 6		237,473		11,144
	$	1,900,083	$	14,182

The following is a summary of current and long-term
notes payable – related parties as of March 31, 2024 and June 30, 2023:

March 31, 2024

Current

Long-Term

Portion

Total

Related entity 1

–

Related entity 2

–

304,684

Related entity 3

–

Related entity 4

–

333,004

Related entity 5

–

Related entity 6

–

637,688

	June 30, 2023
	Current		Long-Term
	Portion		Portion		Total
Related entity 1	$	–	$	1,380,672	$	1,380,672
Related entity 2		–		126,864		126,864
Related entity 3		–		105,000		105,000
Related entity 4		14,132		35,942		50,074
Related entity 5		–		–		–
Related entity 6		237,473		–		237,473
	$	251,605	$	1,648,478	$	1,900,083

All notes dated December 31, 2022, and prior are
unsecured, bear interest at 3% per annum, and are due 360 days from the date of issuance, ranging from June 25, 2020, to December 30,
2022. All notes dated after December 31, 2022, are unsecured, bear interest at 8% per annum, and are due 1095 days from the date of issuance.
Each related party has significant influence or common ownership with the Company’s Chief Executive Officer. Several of these notes
are in default. The Company has not received any notices of default or demands for payment. All notes are unsecured and those which are
past-due are due on demand. As of March 31, 2024 and June 30, 2023, total accrued interest for Notes Payable-Related Parties was $0 and
$14,182, respectively. The Company recorded interest expense from Notes Payable-Related Party for the nine months ended March 31, 2024,
and 2023, of $220,496 and $605,156, respectively.

Related entity 6 carries an annual interest rate
of 30%
and is collateralized by the accounts receivable of Watson Rx. Related entity 4 has multiple loans which include interest rates at 3%,
8% and 10% and are not collateralized.

Schedule of note payable
	March 31,		June 30,
	2024		2023
Current portion	$	1,733,071	$	439,562
Long-term portion		2,281,129		1,011,395
Total	$	4,014,200	$	1,450,957

Notes Payable

Pacific Stem and DCI’s Economic Injury Disaster
Loans (“EIDL”) loans, dated June 7, 2020 and May 10, 2020, respectively, include a 3.75% interest rate for up to 30 years;
the payments are deferred for the first two years (during which interest will accrue), and payments of principal and interest are made
over the remaining 28 years. The EIDL loan has no penalty for prepayment. The EIDL loans attach collateral which includes the following
property that EIDL borrower owns or shall acquire or create immediately upon the acquisition or creation thereof: all tangible and intangible
personal property, including, but not limited to: (a) inventory, (b) equipment, (c) instruments, including promissory notes (d) chattel
paper, including tangible chattel paper and electronic chattel paper, (e) documents, (f) letter of credit rights, (g) accounts, including
health-care insurance receivables and credit card receivables, (h) deposit accounts, (i) commercial tort claims, (j) general intangibles,
including payment intangibles and software and (k) as-extracted collateral as such terms may from time to time be defined in the Uniform
Commercial Code. The security interest the EIDL borrower grants includes all accessions, attachments, accessories, parts, supplies and
replacements for the collateral, all products, proceeds and collections thereof and all records and data relating thereto. The balance
of Pacific Stem’s EIDL is $149,900 as of March 31, 2024 and June 30, 2023, respectively. The balance of DCI’s EIDL is $141,228
and $147,807 as of March 31,2024 and June 30, 2023, respectively. The EIDL loans are technically in default as a result of a change in
ownership without the Small Business Administration (“SBA”) prior written consent. The Company has contacted the SBA regarding
the transfer of ownership documentation and has not yet finalized the transfer of ownership of the EIDL loans.

Likido’s COVID-19 Government Loan includes
a 2.5% interest rate for up to six years; the payments are deferred for the first year (during which interest will accrue). The balance
of COVID-19 Government Loan is $27,321 and $36,475 as of March 31, 2024 and June 30, 2023, respectively.

Watson has a loan totaling $96,436 and $320,709
as of March 31, 2024 and June 30, 2023, respectively, which includes an interest rate of 5% with a maturity date of April 29, 2025. The
loan is collateralized by personal property and includes monthly payments in the amount of $2,656, with a balloon payment at the maturity
date in the amount of $96,436. Watson renewed a loan on June 26, 2023, for $176,836, which includes an interest rate equal to the Wall
Street Journal Prime Rate, or 8.5% and 8.25% as of March 31, 2024 and June 30, 2023, respectively, and has a maturity date of June 26,
2024. The loan is collateralized by the accounts receivable of Watson and includes four payments of $46,838.

On July 25, 2023, Genefic Inc. entered into an
agreement with OnPoint LTB, LLC, for a credit line and funding of up to $2,000,000. The terms of the credit line include a 24-month term
loan, with interest only for 6 months, then amortizing over 18 months down to 50%, with the remaining 50% of the balance due at the end
of term. Interest is fixed at 20% per annum, with an origination fee of $20,000 which is added to the loan balance. Genefic borrowed the
first installment of $1,200,000 at the time of closing and the remaining $800,000 was borrowed on October 4, 2023. As part of the loan
origination fee, the Company issued 500,000 shares of its common stock. The transaction includes a debt discount of $189,971 which is
amortized using an effective interest method over a 24-month period. The net balance of the loan is $1,713,034 as of March 31, 2024.

On January 4, 2024, Genefic Specialty Rx, Inc.
executed a revenue purchase agreement for $350,000, which includes a 17% purchase percent and a total purchased amount of $507,500 at
the end of the term. The agreement includes a $10,500 underwriting fee and a $10,500 origination fee.

On January 22, 2024, Genefic Specialty Rx, Inc.
executed a loan and security agreement whereby Genefic Specialty Rx, Inc. can borrow 80% of the estimated accounts receivable at 2% interest
per month for up to a maximum draw down of 1,250,000. The agreement includes a $5,000 expense deposit.

Convertible Notes

On February 4, 2022, the Company entered into
a securities purchase agreement (“SPA”) with YA II PN, Ltd. (the “Buyer”) for issuance and sale of convertible
debentures (the “Debentures”) in the aggregate principal amount of $3,000,000, including net proceeds received of $2,880,000
from February to March 2022.

The Debentures had a fixed conversion price of
$0.9151 per share (the “Fixed Conversion Price”). The principal and interest, which accrued at a rate of 5% per annum, payable
under the Debentures matures 15 months from the issuance date (the “Maturity Date”), unless earlier converted or redeemed
by the Company. At any time before the Maturity Date, the Buyer had the option to convert the Debentures into the Company’s common
stock at the Fixed Conversion Price. Beginning on May 1, 2023, and continuing on the first day of each calendar month thereafter through
February 1, 2023, the Principal amount plus a 20% redemption premium and plus accrued and unpaid interest was subject to monthly redemption
(“Monthly Redemption”). Under Monthly Redemption, the Company redeemed an applicable redemption amount in accordance with
the redemption schedule provided in the Debenture, which is subject to pro rata adjustment to reflect the conversion or redemption otherwise
effected pursuant to the Debenture contemporaneous with or prior to the scheduled redemption date, in cash, in common stock through the
Buyer’s conversion of the Debenture (at any time after the applicable redemption date), or a combination of both at the Company’s
option. With respect to each Monthly Redemption, all or partially in common stock, the conversion price shall be the lower of (1) the
Fixed Conversion Price, or (2) 100% of the lowest daily VWAP during the ten consecutive trading days immediately preceding the date of
conversion (the “Variable Conversion Price”). The conversion price was adjusted from time to time pursuant to the other terms
and conditions of the Debenture. At no point could the conversion price be less than $0.01.

The Company, in its sole discretion, had the option
to redeem in cash amounts owed under the Debentures prior to the Maturity Date by providing the Buyer with advance written notice at least
10 trading days prior to such redemption, provided that the Shares are trading below the Fixed Conversion Price at the time of the redemption
notice. The Company had to pay a redemption premium equal to 20% (the “Redemption Premium”) of the principal amount being
redeemed.

In connection with the Debenture, the Company
issued to the Buyer warrants equal to 30% coverage exercisable at a strike price equal to the Fixed Conversion Price determined at the
date of the initial closing, or a total of 983,499 warrants to purchase common stock. The Warrants shall be exercisable for four years
and shall be exercised on a cash basis provided the Company is not in default and the shares underlying the Warrant are subject to an
effective registration statement at the time of the Investor’s exercise. There is a cashless provision.

The Company analyzed the conversion feature of
the warrants and determined they did not need to be bifurcated under ASC 815. Based on adoption of ASU-2020-06, the debt was accounted
for as traditional convertible debt with no portion of the proceeds attributed to the conversion feature. The warrants issued with the
debt were accounted for as a debt discount and amortized as interest expense over the life of the note. The warrants were valued using
the Monte Carlo model and the Company recognized $1,427,495 as a debt discount. Key variables used in the valuation are as follows:

Schedule of key variables
Volatility	Risk Free Rate	Stock Price	Term Remaining (Yrs)
225.50%	1.16%	$0.59	0.0

In connection with the Debenture, the Company
incurred $120,000 in issuance costs. Furthermore, the Company issued 192,000 shares of common stock to the Buyer and broker at a fair
value of $115,200. Both the issuance costs and fair value of common stock were recorded as a debt discount.

The total debt discounts related to the convertible
notes were $1,659,442 and amortized using a straight-line method over a fifteen-month period. During the quarter ended March 31, 2024,
and 2023, the Company amortized $0 and $406,932 of debt discount, incurred interest expense of $0 and $13,226, and accrued interest of
$0 and $4,965, respectively.

The total redemption premiums related to the convertible
notes were $600,000 and amortized using a straight-line method over a 10-month period, starting in May 2022. During the nine months ended
March 31, 2024, and 2023, the Company paid redemption premiums related to cash of $0 and $120,000, and stock of $0 and $120,000, respectively.
In addition, the Company recorded accretion of $0 and $180,000 related to interest expense, respectively.

During the nine months ended March 31, 2024, and
2023, the Company redeemed cash of $0 and $600,000, and debentures of $0 and $300,000, respectively.

The net balance of the convertible note was $0
as of March 31, 2024, and June 30, 2023.

7.	Convertible Note Payable – Related Parties

On February 1, 2022, $6,532,206 of related party
debt principal and interest related to promissory notes issued by the Company, with the option for conversion, was converted into 10,002
shares of Series G Convertible Preferred Stock (“Series G Stock”). The Series G Stock shall convert at one share of Series
G Stock to 2,177 shares of common stock (equivalent to converting the related dollars into common shares at $0.30 per share).

On April 4, 2023, $4,544,224 of related party
debt principal and interest related to promissory notes issued by the Company, with the option for conversion, was converted into 15,002
shares of Series H Convertible Preferred Stock (“Series H Stock”). The Series H Stock shall convert at one share of Series
H Stock to 3,029 shares of common stock (equivalent to converting the related dollars into common shares at $0.10 per share).

On June 23, 2023, $29,315,320 of related party
debt principal and interest related to promissory notes issued by the Company, with the option for conversion, was converted into 35,108
shares of Series I Convertible Preferred Stock (“Series I Stock”). The Series I Stock shall convert at one share of Series
I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share).

On March 29, 2024, $13,318,783 of related party
debt principal and interest related to promissory notes issued by the Company, with the option for conversion, was converted into 15,951
shares of Series I Convertible Preferred Stock (“Series I Stock”). The Series I Stock shall convert at one share of Series
I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share).

8.	Related Party Transactions

During the three months and nine months ended
March 31, 2024, the Company received cash funding or expenses paid on behalf of the Company from related parties totaling $1,059,600 and
$2,913,980 respectively. The expenses paid on their behalf primarily relate to operational expenditure and payroll. In most cases, promissory
notes were created on a quarterly basis totaling the amounts referenced above. The remaining amounts are included within accounts payable
– related parties for which the related parties expect repayment. The above-referenced expenses relate to three corporations that
the Company has classified as related parties. These corporations are all owned and/or operated by an individual who has a familial relationship
with the Company’s CEO.

As of March 31, 2024 and June 30, 2023 amounts
included within accounts payable and accrued liabilities – related parties for related party expenses was $254,295 and 547,949,
respectively.

The following is a summary of revenues recorded
by the Companies to related parties with common ownership:

Schedule of revenues
	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2024		2023		2024		2023
Dalrada Health	$	–	$	1,336	$	–	$	75,335
Dalrada Energy Services		5,165		11,379		10,207		40,871
Ignite		–		–		140		–
Prakat		–		15,000		15,000		20,000
Bothof Brothers		519,664		156,173		1,614,458		782,442
	$	524,829	$	183,888	$	1,639,805	$	918,648

See Notes 6, 7, 9, 10, and 11 for additional related
party transactions.

9.	Preferred Stock

The Company has 100,000 shares authorized of Series
F Preferred Stock (“Series F Stock”), par value, $0.01, of which 5,000 shares of Series F Stock (at a fair value of $170)
were issued to the CEO in December 2019. Each share of Series F Stock entitles the holder to the greater of (i) one hundred thousand votes
for each share of Series F Stock, or (ii) the number of votes equal to the number of all outstanding shares of Common Stock, plus one
additional vote such that the holders of Series F Stock shall always constitute most of the voting rights of the Corporation. In any vote
or action of the holders of the Series F Stock voting together as a separate class required by law, each share of issued and outstanding
Series F Stock shall entitle the holder thereof to one vote per share. The holders of Series F Stock shall vote together with the shares
of Common Stock as one class.

On February 1,
2022, the Company converted $6,532,206
of related party debt principal and interest into 10,002
shares of Series G Convertible Preferred Stock (“Series G Stock”). The Series G Stock shall convert at one share of
Series G Stock to 2,177 shares of common stock (equivalent to converting the related dollars into common shares at $0.30 per share).
Series G Stock does not have voting rights.

On April 4, 2023, the
Company converted $4,544,224 of related party debt principal and interest into 15,002 shares of Series H Convertible Preferred Stock (“Series
H Stock”). The Series H Stock shall convert at one share of Series H Stock to 3,029 shares of common stock (equivalent to
converting the related dollars into common shares at $0.10 per share). Series H Stock does not have voting rights.

On June 23, 2023,
the Company converted $29,315,320 of related party debt principal and interest into 35,108 shares of Series I Convertible Preferred
Stock (“Series I Stock”). The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common
stock (equivalent to converting the related dollars into common shares at $0.167 per share). Series I Stock does not have voting
rights.

There were various related party debt convertible
notes that occurred during 2024 and 2023 (see “Note 7. Convertible Note Payable – Related Parties” for more information).

In January 2024, the Company confirmed 100,000
preferred shares authorized.

10.

Stockholders’ Equity

Common Stock Transactions – Fiscal 2024

In July 2023, the Company issued 500,000 shares
of common stock pursuant to a loan agreement for $60,000.

In July 2023, the Company issued 109,637 shares
of common stock pursuant to the Stock Purchase Agreement with Prakat Solutions Inc. for $14,413.

In September 2023, the Company issued 125,000
shares of common stock related to the acquisition of Watson for $37,500.

In October 2023 the company issued 500,000 shares
of common stock pursuant to a loan agreement for $173,000.

In December 2023, the Company issued 125,000 shares
of common stock related to the acquisition of Watson for $26,500.

In December 2023, the Company issued 333,333 shares
of common stock related to the acquisition of DepTec (SSCe) for $70,667.

In January 2024, the Company reduced the number
of authorized shares from 1,000,000,000 to 500,000,000.

In February 2024, the Company issued 4,666,665 shares of common stock
related to a Company conducted private placement for $604,000.

In February 2024, the Company issued 1,200,000
shares of common stock pursuant to consulting agreements resulting in $241,200
in consultancy fees. The fair value of these shares was based upon the quoted closing trading price.

Common Stock Transactions – Fiscal 2023

In July 2022, November 2022, December 2022, March
2023 and June 2023, the Company issued a total of 1,999,998 shares of common stock related to the acquisition of DepTec (SSCe).

In July 2022, the Company issued 500,000 shares
of common stock pursuant to a consulting agreement for management services.

In December 2022, March 2023 and April 2023, the
Company issued a total of 500,000 shares of common stock related to the acquisition of Watson.

In September 2022, December 2022, and March 2023,
the Company issued a total of 375,000 shares of common stock related to the acquisition of International Health Group.

In September 2022 and December 2022, the
Company issued a total of 175,000 shares of common stock related to the acquisition of Pacific Stem Business.

During the nine months ended March 31, 2023, the
Company issued 10,974,521 shares of common stock pursuant to the conversion of $1,475,608 of convertible debt and its related premium
and interest expense.

11.

Stock-Based Compensation

Dalrada Financial Corp 2020 Stock Compensation
Plan

On July 9, 2020, the Board authorized the Dalrada
Financial Corp 2020 Stock Compensation Plan to be used to compensate the company board of directors. The plan allocates the issuance
of up to 3,500,000
shares. On February 25, 2021, the Company amended the plan to issue up to 4,500,000
shares and issued an aggregate of 4,500,000
common shares, or 500,000 shares to each board member (9). 3,500,000
shares of common stock were granted on July 9, 2020, at $0.08 per share and 1,000,000
shares of common stock were granted on February 25, 2021, at $0.45 per share, for a total fair value of $730,000,
which is included in the Consolidated Statements of Operations.

On May 10, 2021, the Company granted 1,000,000
options to purchase common stock to its Chief Financial Officer with an exercise price of $0.47 per share. The options expire in ten years
after issuance. The fair value of the options granted was $0.43 per share, or $430,027 which was calculated using the Black-Scholes model.

On November 10, 2021, the Company cancelled 6,500,000
shares issued to the Board of Directors and issued 6,500,000 cashless warrants. 4,500,000 cashless warrants were to vest immediately,
and 2,000,000 cashless warrants were to vest over a 12-month period. All cashless warrants carry a $0.45 exercise price and a ten-year
term. The Company recorded stock-based compensation related to the 6,500,000 shares in prior periods. The issuance of the warrants was
treated as a modification and, as a result of the value of the stock-based compensation of the shares cancelled being greater than the
stock-based compensation related to the cashless warrants issued, no additional stock-based compensation expense was recorded for the
year ended June 30, 2022.

On November 30, 2021, the Company issued 2,275,000
cashless warrants to employees and consultants for services performed. 825,000 cashless warrants vested immediately and 1,450,000 cashless
warrants vests over a 36-month period. The cashless warrants include an exercise price of $0.45 per share. The cashless warrants expire
in ten years after issuance. The fair value of the cashless warrants granted was $0.73 per share, or $1,651,093 which was calculated using
the Black-Scholes model.

On February 16, 2022, the Company issued 2,250,000
cashless warrants to new members of the Board of Directors. The cashless warrants vest over a 12-month period and hold an exercise price
of $0.45 per share. The cashless warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $0.59
per share, or $1,338,644 which was calculated using the Black-Scholes model.

On August 11, 2022, the Company issued 2,200,000
cashless warrants to new members of the Board of Directors and Advisors. 1,500,000 cashless warrants vest over a 12-month period and hold
an exercise price of $0.45 per share. 450,000 cashless warrants vest over a 12-month period and hold an exercise price of $0.41 per share.
250,000 cashless warrants vest over a 12-month period beginning April 8, 2023 and hold an exercise price of $0.45 per share. The cashless
warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $0.18 per share, or $397,890 which was
calculated using the Black-Scholes model.

On October 7, 2022, the Company issued 3,000,000
cashless warrants to the selling shareholder of Bothof in connection with acquisition of Bothof. The warrants vest over a 24-month period
and hold an exercise price of $0.15 per share. The cashless warrants expire in ten years after issuance. The fair value of the cashless
warrants granted was $1.26 per share, or $5,101,223 which was calculated using the Fair Value method. The cashless warrants are contingent
on the selling shareholder’s continued employment with the Company; therefore, it is treated as stock-based compensation expense
and recognized ratably over a 24-month period.

On March 1, 2023, the Company issued 1,000,000
cashless warrants to the selling shareholders of Dalrada Technology Ltd with the acquisition of Dalrada Technology Ltd. The warrants vest
over a 36-month period and hold an exercise price of $0.10 per share. The cashless warrants expire in ten years after issuance. The fair
value of the cashless warrants granted was $0.07 per share, or $68,975, which was calculated using the Fair Value method.

On April 14, 2023, the Company authorized and
issued 26,638,500 cashless warrants to various officers, employees, and consultants of the Company. A total of 5,575,000 cashless warrants
vest over a 36-month period and hold an exercise price of $0.45 per share. A total of 3,600,000 cashless warrants vest over a 24-month
period and hold an exercise price of $0.45 per share. A total of 5,000,000 cashless warrants vest over a 36-month period and hold an exercise
price of $0.33 per share. A total of 1,300,000 cashless warrants vest over a 12-month period and hold an exercise price of $0.20 per share.
A total of 500,000 cashless warrants vest over a 12-month period and hold an exercise price of $0.12 per share. A total of 250,000 cashless
warrants vest over a 12-month period and hold an exercise price of $0.45 per share. A total of 20,000 cashless warrants vest over a 12-month
period and hold an exercise price of $0.09 per share. A total of 6,200,000 cashless warrants vest over a 36-month period and hold an exercise
price of $0.16 per share. A total of 2,250,000 cashless warrants vest over a 36-month period and hold an exercise price of $0.25 per share.
A total of 1,143,500 cashless warrants vest over a 36-month period and hold an exercise price of $0.08 per share. The remaining 800,000
cashless warrants vest over a 24-month period and hold an exercise price of $0.14 per share. The cashless warrants expire in ten years
after issuance. The fair value of the cashless warrants granted was $0.08 per share, or $2,143,402, which was calculated using the Black-Scholes
model.

On May 25, 2023, the Company authorized and issued
587,634 cashless warrants to various employees of the Company. A total of 537,634 cashless warrants vest over a 36-month period and hold
an exercise price of $0.45 per share, and the remaining 50,000 cashless warrants vest over a 36-month period and hold an exercise price
of $0.08 per share. The cashless warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $0.10
per share, or $47,408, which was calculated using the Black-Scholes model.

On September 6, 2023, the Company authorized and
issued 15,861,000 cashless warrants to various officers, employees, and consultants of the Company. A total of 6,000,000 cashless warrants
vest over a 24-month period and hold an exercise price of $0.10 per share. A total of 4,200,000 cashless warrants vest over a 36-month
period and hold an exercise price of $0.12 per share. A total of 5,161,000 cashless warrants vest over a 36-month period and hold an exercise
price of $0.17 per share. A total of 500,000 cashless warrants vest over a 36-month period and hold an exercise price of $0.12 per share.
The cashless warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $0.08 per share, or $2,064,699,
which was calculated using the Black-Scholes model.

On December 14, 2023, the Company authorized
and issued 250,000
cashless warrants to various employees of the Company. All 250,000
cashless warrants vest over a 36-month
period and hold an exercise price of $0.17
per share. The cashless warrants expire in ten 10
years after issuance. The fair value of the cashless warrants granted was $0.17 per share, or $42,056,
which was calculated using the Black-Scholes model.

On January 30, 2024, the Company authorized and
issued 5,455,000
cashless warrants to various employees and consultants of the company. A total of 3,250,000
cashless warrants vest over a 36-month
period and hold an exercise price of $0.20
per share. A total of 1,875,000
cashless warrants vest over a 36-month
period and hold an exercise price of $0.12
per share. A total of 80,000
cashless warrants vest over a 30-month
period and hold an exercise price of $0.20
per share. A total of 250,000
cashless warrants vest over a 12-month
period and hold an exercise price of $0.20
per share.

Schedule of warrants outstanding
					Weighted
	Common		Weighted		Average
	Stock		Average		Remaining
	Warrants		Exercise Price		Contractual Life
Outstanding – June 30, 2022		12,025,000		–		8.82
Granted		33,426,134	$	0.29
Exercised		–		–
Forfeited		–		–
Outstanding – June 30, 2023		45,451,134	$	0.33		8.83
Granted		21,566,000	$	0.14
Exercised		–		–
Forfeited		(9,286,111)		–
Outstanding – March 31, 2024		57,731,023	$	0.26		8.55
Exercisable – March 31, 2024		34,013,575	$	0.32		8.08

During the nine months ended March 31, 2024 and
2023, stock-based compensation was $3,205,859 and $2,184,692, respectively. Total unrecognized compensation cost of non-vested warrants
was $4,144,808 on March 31, 2024, which will be recognized through fiscal year ending June 30, 2026.

12.

Segment Reporting

Segment information for the three and nine months
ended March 31, 2024, and 2023 is as follows:

Schedule of segment information
	Three Months Ended March 31, 2024
	Genefic		Dalrada Climate Technology			Dalrada Precision Manufacturing			Dalrada Technologies			Corporate			Consolidated
Revenues	$	8,633,807	$	1,000,419		$	303,406		$	368,159		$	–		$	10,305,791
Income (Loss) from Operations		2,709,652		(1,218,637	)		(106,814	)		(47,191	)		(3,626,742	)		(2,289,732	)


	Three Months Ended March 31, 2023
	Genefic		Dalrada Energy			Dalrada Precision Manufacturing			Dalrada Technologies		Corporate			Consolidated
Revenues	$	4,792,799	$	2,479,876		$	1,692,136		$	509,882	$	–		$	9,474,693
Income (Loss) from Operations		196,516		(1,020,232	)		(166,798	)		160,016		(2,808,722	)		(3,639,220	)


	Nine Months Ended March 31, 2024
	Genefic		Dalrada Climate Technology			Dalrada Precision Manufacturing			Dalrada Technologies			Corporate			Consolidated
Revenues	$	14,867,749	$	3,023,814		$	2,438,030		$	1,072,040		$	–		$	21,401,633
Income (Loss) from Operations		1,821,369		(3,597,922	)		(409,239	)		(153,521	)		(9,247,889	)		(11,587,202	)


	Nine Months Ended March 31, 2023
	Genefic			Dalrada Energy			Dalrada Precision Manufacturing			Dalrada Technologies		Corporate			Consolidated
Revenues	$	9,220,417		$	4,232,134		$	3,866,848		$	1,666,181	$	–		$	18,985,580
Income (Loss) from Operations		(764,615	)		(593,057	)		(1,790,160	)		95,654		(8,325,309	)		(11,377,487	)

Geographic Information

The following table presents revenue by country:

Schedule of revenue by country
	Nine Months Ended
	March 31,
	2024		2023
United States	$	19,167,258	$	16,157,623
Scotland		1,288,443		1,539,371
Spain		125,260		–
India		820,672		1,288,586
	$	21,401,633	$	18,985,580

The following table presents inventories by country:

Schedule of inventories by country
	March 31,		June 30,
	2024		2023
United States	$	833,985	$	584,330
Scotland		1,919,223		1,494,362
	$	2,753,208	$	2,078,692

The following table presents property and equipment,
net, by country:


	March 31,		June 30,
	2024		2023
United States	$	1,226,222	$	1,284,834
Scotland		137,319		182,657
Spain		56,064		–
India		6,223		8,591
	$	1,425,828	$	1,476,082

13.

Commitments and Contingencies

Lease Commitments

The Company determines if an arrangement is a
lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use
of an explicitly or implicitly identified fixed asset for a period in exchange for consideration. Control of an underlying asset is conveyed
to the Company if the Company obtains the rights to direct the use of and to obtain substantially all the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components is recognized
when the obligation is probable.

Operating lease right of use (“ROU”)
assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating
lease payments are recognized as lease expense on a straight-line basis over the lease term. The Company primarily leases buildings (real
estate) which are classified as operating leases. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate
implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate is not
readily determinable in the Company’s leases, the incremental borrowing rate is used based on the information available at commencement
date in determining the present value of lease payments.

The lease term for all the Company’s leases includes
the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate)
the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the
lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority of the Company’s leases
as the reasonably certain threshold is not met.

Lease payments included in the measurement of
the lease liability are comprised of fixed payments, variable payments that depend on index or rate, and amounts probable to be payable
under the exercise of the Company option to purchase the underlying asset if reasonably certain.

Variable lease payments not dependent on a rate
or index associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which
those payments are assessed as probable. Variable lease payments are presented as operating expenses in the Company’s income statement
in the same line item as expense arising from fixed lease payments. As of and during the three and nine months ended March 31, 2024, management
determined that there were no variable lease costs.

Right-of-Use Asset

In July 2022, the Company entered into a five-year
lease agreement to lease a commercial building in Escondido, California. The building is owned by a related party. The Company recognized
a right of use asset and liability of $2,405,540 and used an effective borrowing rate of 3.0% within the calculation. Imputed interest
is $192,521. The lease agreements mature in June 2027.

In April 2023, the Company’s Prakat subsidiary
entered into a lease agreement to lease office space through March 2026. The Company recognized a right of use asset and liability of
$99,060 and used an effective borrowing rate of 8% within the calculation.

In May 2021, the Company’s PSC subsidiary
entered into a three-year and 6-month lease agreement to lease a medical office space in Poway, California. The Company recognized a right
of use asset and liability of $277,856 and used an effective borrowing rate of 3.0% within the calculation.

In January 2022, the Company’s DCI subsidiary
entered into a five-year and 5-month lease agreement to lease a medical office space in Chula Vista, California. The Company recognized
a right of use asset and liability of $287,345 and used an effective borrowing rate of 3.0% within the calculation.

In May 2022, the Company’s DCI subsidiary
entered into a six-year and 3-month lease agreement to lease an office space in San Diego, California. The Company recognized a right
of use asset and liability of $919,722
and used an effective borrowing rate of 4.0%
within the calculation.

In August 2020, the Company’s DepTec subsidiary
entered into a five-year lease agreement to lease office space. The Company recognized a right of use asset and liability of $146,622
and used an effective borrowing rate of 3.0%

In May 2021, the Company’s Watson subsidiary
entered into a three-year lease agreement to lease a building in Florence, Alabama. The Company recognized a right of use asset and liability
of $90,827 and used an effective borrowing rate of 3.0%

In July 2022, the Company’s Empower subsidiary
entered into a five-year lease agreement to lease a commercial space in Escondido, California. The building is owned by a related party.
The Company recognized a right-of-use asset and liability of $322,756 and used an effective borrowing rate of 3.0% within the calculation.
Imputed interest is $25,838. The lease agreement matures in June 2027.

In October 2022, the Company’s Pala Diagnostics
entered into a one-year lease agreement to lease a research and development laboratory space in San Diego, California. The Company recognized
a right-of-use asset and liability of $37,239 And used an effective borrowing rate of 8% within the calculation. Imputed interest is $1,761.
The lease agreement matures in October 2023.

In October 2022, the Company acquired Bothof Brothers
which had an existing lease to a commercial building in Escondido, California. The building is owned by a related party. Upon acquisition,
the company recognized a right-of-use asset and liability of $33,454 and used an effective borrowing rate of 3.0% within the calculation.
Imputed interest is $2,174. The lease agreement matures in December 2024.

In January 2023, the Company’s Solas subsidiary
entered into a one-year lease agreement to lease an office and medical suite in Coronado, California. The company recognized a right of
use asset and liability of $47,211 and used an effective borrowing rate of 8%.

In March 2023, the Company acquired Dalrada Technology
Ltd. which had an existing lease to a commercial building in Livingston, Scotland. Upon acquisition, the company recognized a right-of-use
asset and liability of $540,615 and used an effective borrowing rate of 8.0% within the calculation. Imputed interest is $125,761. The
lease agreement matures in October 2027.

In March 2023, Genefic entered into a five-year
lease agreement to lease a commercial building in San Diego, California. The Company recognized a right-of-use asset and liability of
$844,242 and used an effective borrowing rate of 8.0% within the calculation. Imputed interest is $185,976. The lease agreement matures
in March 2028.

In March 2023, Dalrada Technology Spain S.L. entered
into a five-year lease agreement to lease a commercial building in Bergondo, Spain. The Company recognized a right-of-use asset and liability
of $125,780 and used an effective borrowing rate of 8.0% within the calculation. Imputed interest is $28,129. The lease agreement matures
in May 2028.

In July, 2023, Bothof Brothers entered into a
3-year lease agreement to lease a warehouse in Escondido, California. The Company recognized a right-of-use asset and liability of $342,211
and used an effective borrowing rate of 8.0% within the calculation. Imputed interest is $39,366. The lease agreement matures in February
2026.

The following are the expected maturities of
lease liabilities for operating leases as of March 31, 2024, including the total amount of imputed interest related:

Schedule of minimum lease payments
Fiscal Year Ended June 30,
Remainder 2024	$	381,517
2025		1,438,631
2026		1,351,056
2027		1,232,920
2028		430,907
Thereafter		32,627
Total lease payments		4,867,658
Less: imputed interest		(414,689	)
Present value of lease liability	$	4,452,969

Other information related to operating leases as of March 31,
2024 and June 30, 2023, respectively, were as follows:

Schedule of lease information
	March 31, 2024		June 30, 2023
Weighted average remaining lease term – years		3.35		4.09
Weighted average discount rate		6.85%		6.74%

Legal Proceedings

Genefic Products (“Dalrada Health”),
a subsidiary of Dalrada Financial Corporation, formed a joint venture with Vivera Pharmaceuticals, Inc. (“Vivera”), whereby
Vivera is the minority member. As the managing member of the joint venture, Genefic Products, in December 2021, filed suit against Vivera
and Paul Edalat, Vivera’s Chairman and CEO, for misappropriation of funds on behalf of the joint venture in the amount of $2,104,509.
In addition to filing a cross-complaint against Genefic Products, Vivera filed a separate complaint against Dalrada Financial Corporation,
Empower Genomics (a subsidiary of Dalrada Financial Corporation), Dalrada Financial Corporation’s officers, and other unrelated
parties. The proceedings are being held at the Superior Court of the State of California, for the County of Orange – Central Justice
Center.

In September 2023, Kroger Specialty Pharmacy LLC
(“Kroger”) filed lawsuits/preliminary injunctions against Genefic Specialty Pharmacy and two of its employees who were former
employees of Kroger. The lawsuits were filed in Tennessee and Alabama, respectively. The basis for the injunction arose from a non-compete
clause in the contract between the two employees and a company which was later acquired by Kroger. In April 2024, the Court in the Tennessee
case granted the preliminary injunction on the Tennessee employee. The Alabama case has not yet been ruled on and is expected to be heard
in May 2024.

14.

Subsequent Events

On April 2, 2024, the Company issued 125,000 shares of common stock
as part of the consideration for the acquisition of Watson RX Solution, Inc.

On April 2 and April 16, 2024, the Company issued a total of 666,666
shares of common stock as part of the consideration for the acquisition of DepTec.

On April 5, 2024, Genefic Specialty Rx, Inc. executed
a loan and security agreement whereby Genefic Specialty Rx, Inc. can borrow 80% of the estimated accounts receivable at 2% interest per
month for up to a maximum draw down of $2,300,000. On April 5, 2024, Genefic Specialty Rx, Inc. drew a total of $800,000 on the loan.

On April 9, 2024, the Company executed a Promissory
Note for $172,5000, which includes an original issue discount of $22,500 and $6,000 in closing expenses. The Promissory Note carries an
interest rate of 14% per annum and a 10-month term.

On April 29, 2024, the Company executed a revenue purchase agreement
for $600,000, which includes a $6,000 underwriting fee, $6,000 origination fee and $50 wire fee. The term of the agreement is 42 weeks
and includes a total payback of $798,025.

On May 7, 2024 (“Purchase Date”), the Company’s
subsidiary, Genefic Infusion RX, Inc., executed a Membership Purchase Agreement to acquire 100% of IV Services, LLC (“IV
Services”) with a purchase price of $500,000 plus the cost of inventory as of the Purchase Date. IV Services is a pharmacy
business which provides goods and services, including home infusion services in the parishes of Orleans, Jefferson, St. Bernard,
Plaquemines, St. Tammany, St. Charles, St. John the Baptist, Iberville and Pointe Coupe, Louisiana. IV Services holds pharmacy
license in both Louisiana and Mississippi. The Company will not assume any liabilities as of the Purchase Date.

Item 2. Management’s Discussion and Analysis
of Financial Condition and Results of Operations of Dalrada Financial Corporation for the Three and nine months ended March 31, 2024,
and 2023.

You should read the following discussion and analysis
in conjunction with our financial statements, including the notes thereto, included in this Report. Some of the information contained
in this Report may contain forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1933, as amended
(the “Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This information
may involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, or achievements
to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking
statements which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by the use
of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,”
“believe,” “intend” or “project” or the negative of these words or other variations on these words
or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance
that the projections included in these forward-looking statements will come to pass. Our actual results could differ materially from those
expressed or implied by the forward-looking statements as a result of various factors. We undertake no obligation to update publicly any
forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

Our net loss and limited working capital raise
substantial doubt about our ability to continue as a going concern. We incurred a net loss of $2,907,607 and $13,185,923 during the three
and nine months ended March 31, 2024, respectively. We will be required to raise substantial capital to fund our capital expenditures,
working capital, and other cash requirements. We will continue to rely on related parties and seek other financing to complete our business
plans. The successful outcome of future financing activities cannot be determined at this time and there are no assurances that, if achieved,
we will have sufficient funds to execute our intended business plan or generate positive operational results.

In addition to our current deficit, we may incur
additional losses during the foreseeable future, until we are able to successfully execute our business plan. There is no assurance that
we will be able to obtain additional financing through private placements and/or public offerings necessary to support our working capital
requirements. To the extent that funds generated from any private placements and/or public offerings are insufficient, we will have to
raise additional working capital through other sources, such as bank loans and/or financings. No assurance can be given that additional
financing will be available, or if available, will be on acceptable terms.

We are incurring increased costs as a result of
being a publicly traded company. As a public company, we incur significant legal, accounting and other expenses that we did not incur
as a private company. In addition, the Sarbanes-Oxley Act of 2002, as well as new rules subsequently implemented by the Securities and
Exchange Commission, have required changes in corporate governance practices of public companies. These new rules and regulations have
increased our legal and financial compliance costs and have made some activities more time-consuming and costly. For example, as a result
of becoming a public company, we have created additional board committees and have adopted policies regarding internal controls and disclosure
controls and procedures. In addition, we have incurred additional costs associated with our public company reporting requirements. As
a result of the new rules, it may become more difficult for us to attract and retain qualified persons to serve on our Board of Directors
or as executive officers. We cannot predict or estimate the amount of additional costs we may incur as a result of being a public company
or the timing of such costs.

RESULTS OF OPERATIONS

Three Months Ended March 31, 2024 and 2023

The following table sets forth the results of
our operations for the three months ended March 31, 2024 and 2023:

	Three Months Ended March 31, 2024
	Genefic		Dalrada Climate Technology			Dalrada Precision Manufacturing			Dalrada Technologies			Corporate			Consolidated
Revenues	$	8,633,807	$	1,000,419		$	303,406		$	368,159		$	–		$	10,305,791
Income (Loss) from Operations		2,709,652		(1,218,637	)		(106,814	)		(47,191	)		(3,626,742	)		(2,289,732	)

	Three Months Ended March 31, 2023
	Genefic		Dalrada Energy			Dalrada Precision Manufacturing			Dalrada Technologies		Corporate			Consolidated
Revenues	$	4,792,799	$	2,479,876		$	1,692,136		$	509,882	$	–		$	9,474,693
Income (Loss) from Operations		196,516		(1,020,232	)		(166,798	)		160,016		(2,808,722	)		(3,639,220	)

Revenues and Cost of Revenues

Revenues

Genefic:

Revenues for the three months ended March 31,
2024, was $8,633,807 compared with revenue of $4,792,799 during the three months ended March 31, 2023, an increase of 80.1%. The increase
in revenues was primarily attributable to the increased activity for Genefic Specialty Pharmacy (formerly Watson).

Dalrada Climate Technology:

Revenues for the three months ended March 31,
2024, was $1,000,419 compared with revenue of $2,479,876 during the three months ended March 31, 2023, a decrease of $1,479,457, or 59.7%.
The decrease is due to the reduced activity in the Averett University project when comparing the three months ended March 31, 2024 and
2023 respectively.

Dalrada Precision Manufacturing:

Revenues for the three months ended March 31,
2024, was $303,406 compared with revenue of $1,692,136 during the three months ended March 31, 2023, a decrease of $1,388,730, or 82.1%.
The decrease in revenue is primarily attributable to the decreased sales activity in the Precision Parts sector.

Dalrada Technologies:

Revenues for the three months ended March 31,
2024, was $368,159 compared with revenue of $509,882 during the three months ended March 31, 2023, a decrease of $141,723, or 27.8%. The
decrease in revenue was a result of completing customer contracts while not entering into larger, new contracts.

Costs and Expenses

Cost of Revenues

Genefic:

Cost of Revenues for the three months ended March
31, 2024, was $4,127,905 compared to cost of revenues of $2,596,376 during the three months ended March 31, 2023, an increase of $1,531,529,
or 59.0%. The increase in cost of revenues was primarily a result of an increase in lower margin pharmaceutical sales related to Genefic
Specialty Pharmacy.

Dalrada Climate Technology:

Cost of Revenues for the three months ended March
31, 2024, was $1,105,979, compared to cost of revenues of $2,918,601 during the three months ended March 31, 2023, a decrease of $1,812,622,
or 62.1%. The decrease is due to the reduced activity in the Averett University project when comparing the three months ended March 31,
2024 and 2023 respectively.

Dalrada Precision Manufacturing:

Cost of Revenues for the three months ended March
31, 2024, was $150,022 compared to cost of revenues of $936,415 during the three months ended March 31, 2023, a decrease of $786,415,
or 84.0%. The decrease in cost of revenue is due to the decreased activity for the Dalrada Precision Parts sales.

Dalrada Technologies:

Cost of Revenues for the three months ended March
31, 2024, was $210,432 compared to cost of revenues of $161,266 during the three months ended March 31, 2023, an increase of $49,166 or
30.5%. The increase in cost of revenues was primarily a result of the higher cost of labor.

Operating Expenses

Genefic:

Operating expenses for the three months ended
March 31, 2024, was $1,796,250 compared to operating expenses of $1,999,907 during the three months ended March 31, 2023, a decrease of
$203,657 or 10.2%. The decrease in operating expenses was the result of the decrease in legal and professional fees incurred.

Dalrada Climate Technology:

Operating expenses for the three months ended
March 31, 2024, was $1,113,077 compared to operating expenses of $581,507 during the three months ended March 31, 2023, an increase of
$531,570, or 91.4%. The increase in operating expenses was a result of the integration of the Bothof Brothers and Dalrada Technology Spain
to the segement during the three months ended March 31, 2024.

Dalrada Precision Manufacturing:

Operating expenses for the three months ended
March 31, 2024 was $260,198 compared to operating expenses of $922,497 during the three months ended March 31, 2023, a decrease of $662,299
or 71.8%. The decrease in operating expenses was a result of decreased legal and professional fees incurred.

Dalrada Technologies:

Operating expenses for the three months ended
March 31, 2024 was $204,918 compared to operating expenses of $188,600 during the three months ended March 31, 2023, an increase of $16,318,
or 8.7%. The increase in operating expenses was primarily attributable to the increase in miscellaneous operating expenses.

Corporate:

Operating expenses for the three months ended
March 31, 2024 was $3,626,742 compared to operating expenses of $2,808,722 during the three months ended March 31, 2023, an increase of
$818,020, or 29.1%. During the three months ended March 31, 2024 and 2023, the Company recorded stock compensation expense of $1,077,390
and $815,454, respectively, to consultants, employees, executives, and the Board of Directors, which is included in operating expenses.

Other Income (Expense)

Other income (expense) consists of penalties and
interest within interest expense on the consolidated statements of operations. Interest expense was $347,317 and $314,319 for the three
months ended March 31, 2024 and 2023, respectively.

Net Income (Loss)

Net loss for the three months ended March 31,
2024 was $2,907,607 compared to net loss of $4,045,935 for the three months ended March 31, 2023.

Nine Months Ended March 31, 2024 and 2023

The following table sets forth the results of
our operations for the nine months ended March 31, 2024 and 2023:

	Nine Months Ended March 31, 2024
	Genefic		Dalrada Climate Technology			Dalrada Precision Manufacturing			Dalrada Technologies			Corporate			Consolidated
Revenues	$	14,867,749	$	3,023,814		$	2,438,030		$	1,072,040		$	–		$	21,401,633
Income (Loss) from Operations		1,821,369		(3,597,922	)		(409,239	)		(153,521	)		(9,247,889	)		(11,587,202	)

	Nine Months Ended March 31, 2023
	Genefic			Dalrada Energy			Dalrada Precision Manufacturing			Dalrada Technologies		Corporate			Consolidated
Revenues	$	9,220,417		$	4,232,134		$	3,866,848		$	1,666,181	$	–		$	18,985,580
Income (Loss) from Operations		(764,615	)		(593,057	)		(1,790,160	)		95,654		(8,325,309	)		(11,377,487	)

Revenues and Cost of Revenues

Revenues

Genefic:

Revenues for the nine months ended March 31, 2024,
was $14,867,749 compared with revenue of $9,220,417 during the nine months ended March 31, 2023, an increase of $5,647,332, or 61.2%.
The increase in revenues was primarily attributable to the increase in activity for Genefic Specialty Pharmacy.

Dalrada Climate Technology:

Revenues for the nine months ended March 31, 2024,
was $3,023,814 compared with revenue of $4,232,134 during the nine months ended March 31, 2023, a decrease of $1,208,320, or 28.6%. The
decrease in revenue was primarily attributable to the reduction in activity at Dalrada Energy Services.

Dalrada Precision Manufacturing:

Revenues for the nine months ended March 31, 2024,
was $2,438,030 compared with revenue of $3,866,848 during the nine months ended March 31, 2023, a decrease of $1,428,818, or 37.0%. The
decrease in revenues was primarily attributable to the reduction in activity for Dalrada Precision Parts. .

Dalrada Technologies:

Revenues for the nine months ended March 31, 2024,
was $1,072,040 compared with revenue of $1,666,181 during the nine months ended March 31, 2023, a decrease of $594,141, or 35.7%. The
decrease in revenue was a result of completing customer contracts while not entering into larger, new contracts.

Costs and Expenses

Cost of Revenues

Genefic:

Cost of Revenues for the nine months ended March
31, 2024, was $8,221,867 compared to cost of revenues of $4,859,485 during the nine months ended March 31, 2023, an increase of $3,362,382,
or 69.2%. The increase in cost of revenues was primarily a result of an increase in lower margin pharmaceutical sales related to Genefic
Specialty Pharmacy.

Dalrada Climate Technology:

Cost of Revenues for the nine months ended March
31, 2024, was $3,351,694, compared to cost of revenues of $3,633,781 during the nine months ended March 31, 2023, a decrease of $282,087,
or 7.8%. The decrease in cost of revenues was primarily a result of the reduction in activity for Dalrada Energy Services.

Dalrada Precision Manufacturing:

Cost of Revenues for the nine months ended March
31, 2024, was $1,477,562 compared to cost of revenues of $2,441,904 during the nine months ended March 31, 2023, a decrease of $964,342,
or 39.5%. The decrease in cost of revenue is due to decrease activity for Dalrada Precision Parts.

Dalrada Technologies:

Cost of Revenues for the nine months ended March
31, 2024, was $666,439 compared to cost of revenues of $988,970 during the nine months ended March 31, 2023, a decrease of $322,531 or
32.6%. The decrease in cost of revenues was primarily a result of the decrease in sales volume for the period.

Operating Expenses

Genefic:

Operating expenses for the nine months ended March
31, 2024, was $4,824,513 compared to operating expenses of $5,125,547 during the nine months ended March 31, 2023, a decrease of $301,034,
or 5.9%. The decrease in operating expenses was the result of a decrease in legal and professional fees incurred.

Dalrada Climate Technology:

Operating expenses for the nine months ended March
31, 2024, was $3,270,042 compared to operating expenses of $1,191,410 during the nine months ended Marchr 31, 2023, an increase of $2,078,632,
or 174.5%. The increase in operating expenses was a result an increase in salaries and wages due to expansions to Spain and the continued
growth of Bothof Brothers.

Dalrada Precision Manufacturing:

Operating expenses for the nine months ended March
31, 2024 was $1,369,707 compared to operating expenses of $3,215,104 during the nine months ended March 31, 2023, a decrease of $1,845,397,
or 57.4%. The decrease in operating expenses was a result of decreased legal and professional fees incurred.

Dalrada Technologies:

Operating expenses for the nine months ended March
31, 2024 was $559,122 compared to operating expenses of $581,557 during the nine months ended March 31, 2023, a decrease of $22,435, or
3.9%. The decrease in operating expenses was primarily attributable to the decrease in various miscellaneous expenses.

Corporate:

Operating expenses for the nine months ended March
31, 2024 was $9,247,889 compared to operating expenses of $8,325,309 during the nine months ended March 31, 2023, an increase of $922,580,
or 11.1%. During the nine months ended March 31, 2024 and 2023, the Company recorded stock compensation expense of $3,205,859 and $2,184,692,
respectively, to consultants, employees, executives, and the Board of Directors, which is included in operating expenses.

Other Income (Expense)

Other income (expense) consists of penalties and
interest within interest expense on the consolidated statements of operations. Interest expense was $674,470 and $2,207,049 for the nine
months ended March 31, 2024 and 2023, respectively.

Net Income (Loss)

Net loss for the nine months ended March 31, 2024
was $13,185,923 compared to net loss of $11,698,139 for the nine months ended March 31, 2023.

Liquidity and Capital Resources

The Company continues to incur significant losses
and raises substantial doubt regarding the Company’s ability to continue as a going concern. We anticipate needing additional liquidity
during the next twelve months to fund operations, expand our subsidiaries, expand the growth of the COVID-19 testing segment, continue
the commercialization of our Likido heating & cooling units and growing the Dalrada Energy Services subsidiary. Management is planning
to support operations by raising capital, and by accelerating sales & marketing efforts of high-margin heating & cooling units,
precision parts, Dalrada Energy Services, DepTec’s deposition systems and COVID-19 testing. The continuation of the Company as a
going concern is dependent upon the continued financial support from its management, its ability to obtain the necessary debt or equity
financing and generate profitable operations from the Company’s planned future operations. We will continue to rely on equity sales
of our common shares in order to continue to fund our business operations. Issuances of additional shares will result in dilution to existing
stockholders. There is no assurance that we will achieve any additional sales of the equity securities or arrange for debt or other financing
to fund planned acquisitions and activities and there are no plans to induce conversion of existing debt. There are no assurances that
our plans will be successful. These financial statements do not include any adjustments to the recoverability and classification of recorded
asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Our primary sources of liquidity are cash from
operations and cash on hand from related party loans. Our primary requirements for liquidity are to fund our working capital needs, debt
service, operating lease obligations, capital expenditures and general corporate needs.

As of March 31, 2024, we maintained a cash and
cash equivalents balance of $533,595 with a working capital of $5,327,995.

Working Capital

As of March 31, 2024, the Company had current
assets of $15,883,157 and current liabilities $10,555,162 compared with current assets of $9,817,045 and current liabilities of $10,019,465
on June 30, 2023. The decrease in the working capital was primarily a result of increased accounts payable to fund payroll and pay outstanding
vendors.

Cash Flows

	Nine Months Ended
	March 31,
	2024			2023
Net cash used in operating activities	$	(5,660,542	)	$	(10,074,709	)
Net cash used in investing activities		(272,783	)		(878,351	)
Net cash provided by financing activities		5,654,096			11,440,418
Net change in cash during the period, before effects of foreign currency	$	(279,229	)	$	487,358

Cash flow from Operating Activities

During the nine months ended March 31, 2024, the
Company used $5,812,216 of cash for operating activities compared to $10,074,709 used during the nine months ended March 31, 2023. The
primary decrease in the use of cash for operating activities was a result of the reduction in accounts receivable related to the COVID-19
business when compared to the prior year.

Cash flow from Investing Activities

During the nine months ended March 31, 2024, the
Company used $272,783 of cash for investing activities compared to $878,351 used during the nine months ended March 31, 2023. The decrease
in the use of cash for investing activities was primarily due to the purchase of equipment used primarily for the Dalrada Precision Manufacturing
segment in the prior year.

Cash flow from Financing Activities

During the nine months ended March 31, 2024, the
Company received $5,654,096 in cash from financing activities compared to $11,440,418 during the nine months ended March 31, 2023. The
decrease was primarily due to the decrease in proceeds from related party notes payable.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that
have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues
or expenses, results of operations, liquidity, capital expenditures or capital resources, and related party transactions.

Critical Accounting Policies

Our financial statements and accompanying notes
have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation
of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies
and estimates that we use to prepare our financial statements. A complete summary of these policies is included in note (1) of the notes
to our financial statements. In general, management’s estimates are based on historical experience, on information from third party professionals,
and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from
those estimates made by management.

Use of Estimates

The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the amounts reported in the financial statements and accompanying notes for the reporting period. Significant areas requiring the
use of management estimates relate to the valuation of its mineral leases and claims and our ability to obtain final government permission
to complete the project. As of March 31, 2024 there have been no material changes to our critical accounting policies and estimates from
those previously disclosed in our Annual Report on Form 10-K for the year ended June 30, 2023.

Stock-Based Compensation

The Company records stock-based compensation in
accordance with ASC 718, Compensation – Stock Compensation, using the fair value method. All transactions in which goods
or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration
received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees
and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued.

Recently Issued Accounting Pronouncements

We have reviewed all recently issued, but not
yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company.

Contractual Obligations

We are a smaller reporting company as defined
by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable to smaller reporting companies.

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures.
Our Chief Executive Officer and Principal Financial Officer, after evaluating the effectiveness of our “disclosure controls and procedures”
(as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly
Report on Form 10-Q (the “Evaluation Date”), concluded that as of the Evaluation Date, our disclosure controls and procedures
were not effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under
the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission
rules and forms.

(b) Changes in internal control over financial
reporting. There were no changes in our internal control over financial reporting during our most recent fiscal quarter that materially
affected, or were reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Internal
Controls

Disclosure controls and procedures, no matter
how well designed and implemented, can provide only reasonable assurance of achieving an entity’s disclosure objectives. The likelihood
of achieving such objectives is affected by limitations inherent in disclosure controls and procedures. These include the fact that human
judgment in decision-making can be faulty and that breakdowns in internal control can occur because of human failures such as simple errors
or mistakes or intentional circumvention of the established process.

Management’s Report on Internal Control over
Financial Reporting

Our management is responsible for establishing
and maintaining adequate internal control over financial reporting, as such term is defined in the Securities Exchange Act of 1934 Rule
13a-15(f). Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework
in Internal Control – Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (“2013
COSO Framework”).

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

Dalrada Health Products (“Dalarada Health”),
formed a joint venture with Vivera Pharmaceuticals, Inc. (“Vivera”), whereby Vivera is the minority member. As the managing
member of the joint venture, Dalrada Health Products, in December 2021, filed suit against Vivera and Paul Edalat, Vivera’s Chairman
and CEO, for misappropriation of funds on behalf of the joint venture in the amount of $2,104,509. In addition to filing a cross-complaint
against Dalrada Health Products, Vivera filed a separate complaint against Dalrada Financial Corporation, Empower Genomics (a subsidiary
of Dalrada Financial Corporation), Dalrada Financial Corporation’s officers, and other unrelated parties. The proceedings are being
held at the Superior Court of the State of California, for the County of Orange – Central Justice Center. In March 2023, the presiding
judge ordered the case stayed until a valuation could be completed for Pala Diagnostics (“Pala” the company formed as a result
of the joint venture) in order to allow for a dissolution of the partnership as requested by both parties. Any remaining issues found
to be unresolved through the dissolution process will be addressed once the stay is lifted after dissolution.

On January 10, 2023, a resolution was concluded
in the dispute between Likido Ltd. and MAPtech PACKAGING LIMITED (“MAPtech”) whereby Likido shall pay sum of $429,987 in damages,
$42,374 in legal costs, and £19,754 as reimbursement for arbitration fees and expenses paid on account by MAPtech. Likido
Ltd. shall pay interest at a rate of 8% per annum simple on all sums due pursuant to award, beginning 30 days from the date of the award.

Item 1A. Risk Factors.

Not applicable to smaller reporting entities

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Securities.

None.

Item 3. Defaults Upon Senior Securities.

None noted.

Item 4. Mine Safety Disclosures.

Not applicable to our Company.

Item 5. Other Information.

During the quarter ended March 31, 2024, no
director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1
trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits.

Exhibit Number		Exhibit Description
31.1		Certification of the Chief Executive Officer Pursuant to Rule 13a-14 or 15d-14 of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of the Chief Financial Officer Pursuant to Rule 13a-14 or 15d-14 of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		Inline XBRL Instance Document
101.SCH*		Inline XBRL Schema Document
101.CAL*		Inline XBRL Calculation Linkbase Document
101.DEF*		Inline XBRL Definition Linkbase Document
101.LAB*		Inline XBRL Label Linkbase Document
101.PRE*		Inline XBRL Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of Section 13 or
15(d) of the Exchange Act, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

	Dalrada Financial Corporation

	By: /s/ Brian Bonar
Date: May 13, 2024	Brian Bonar
	Chief Executive Officer

Pursuant to the requirements of the Exchange Act
this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date

/s/ Brian Bonar	Chief Executive Officer	May 13, 2024
Brian Bonar	and Director

EXHIBIT
31.1

CERTIFICATION PURSUANT TO

18 USC, ss 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Brian Bonar, certify that:

	1.	I have reviewed this quarterly report on Form 10-Q of Dalrada Financial Corporation;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its condensed consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 13, 2024

/s/ Brian Bonar
Brian Bonar Chief Executive Officer, and Director (Principal Executive Officer)

EXHIBIT
31.2

CERTIFICATION PURSUANT TO

18 USC, ss 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Kyle McCollum, certify that:

	1.	I have reviewed this quarterly report on Form 10-Q of Dalrada Financial Corporation;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its condensed consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 13, 2024

/s/ Kyle McCollum
Kyle McCollum Chief Financial Officerr (Principal Financial Officer and Principal Accounting Officer)

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT
TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Brian Bonar, hereby certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	the Quarterly Report on Form 10-Q of Dalrada Financial Corporation for the period ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Dalrada Financial Corporation

Dated: May 13, 2024


		/s/ Brian Bonar
		Brian Bonar
		Chief Executive Officer, and Director
		(Principal Executive Officer)

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT
TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Kyle McCollum, hereby certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	the Quarterly Report on Form 10-Q of Dalrada Financial Corporation for the period ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Dalrada Financial Corporation

Dated: May 13, 2024


		/s/ Kyle McCollum
		Kyle McCollum
		Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)